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The rapid advancement of the COVID-19 pandemic has prompted an accelerated pursuit
to identify effective therapeutics. Stages of the disease course have been defined by
viral burden, lung pathology, and progression through phases of the immune response.
Immunological factors including inflammatory cell infiltration and cytokine storm have
been associated with severe disease and death. Many immunomodulatory therapies for
COVID-19 are currently being investigated, and preliminary results support the premise
of targeting the immune response. However, because suppressing immune mechanisms
could also impact the clearance of the virus in the early stages of infection, therapeutic
success is likely to depend on timing with respect to the disease course. Azithromycin is
an immunomodulatory drug that has been shown to have antiviral effects and potential
benefit in patients with COVID-19. Multiple immunomodulatory effects have been defined
for azithromycin which could provide efficacy during the late stages of the disease,
including inhibition of pro-inflammatory cytokine production, inhibition of neutrophil influx,
induction of regulatory functions of macrophages, and alterations in autophagy. Here
we review the published evidence of these mechanisms along with the current clinical
use of azithromycin as an immunomodulatory therapeutic. We then discuss the potential
impact of azithromycin on the immune response to COVID-19, as well as caution against
immunosuppressive and off-target effects including cardiotoxicity in these patients.
While azithromycin has the potential to contribute efficacy, its impact on the COVID-19
immune response requires additional characterization so as to better define its role in
individualized therapy.
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INTRODUCTION
Azithromycin is administered to over 40 million patients
annually for its antibacterial activity (1), but characterization
of the immunomodulatory properties of the macrolide
antimicrobials has expanded their use. Clinically, azithromycin
is used to treat bacterial infections of the upper respiratory
tract, but has also been shown to improve lung function in
subjects with various pulmonary pathologies, most notably
in patients with cystic fibrosis (2–6). Mechanistic studies
demonstrate immunomodulatory activity through the regulation
of cellular processes involved in inflammation including NF-
κB signaling (7–12), inflammasome activation (13, 14), and
autophagy flux (15, 16). Although azithromycin inhibits a
variety of pro-inflammatory pathways, it does not result in full
immune suppression as is induced by glucocorticoids and other
immunosuppressive therapies. Rather, azithromycin exhibits
immunomodulatory properties by shifting the inflammatory
response, mainly in macrophages, toward one characterized
by functional aspects of regulation and repair. These effects
position azithromycin to have a profound effect on inflammatory
conditions in which the immune response contributes to
detrimental tissue damage, organ failure, and death.
The emergence of severe acute respiratory syndrome (SARS)-
coronavirus 2 (CoV-2) has thrust azithromycin into the
spotlight due to early reports of improved outcomes in patients
treated with azithromycin and hydroxychloroquine (17). The
immunopathology of Coronavirus Disease 2019 (COVID-19)
that results from SARS-CoV-2 infection is highlighted by weak
innate antiviral responses as a result of inadequate production of
the antiviral cytokines (type I and type III interferons), and robust
pro-inflammatory responses with high levels of chemokine
and cytokine expression (18). In some patients infected with
SARS-CoV-2, pulmonary interstitial fibrosis results due to an
overactive immune response to the infection (19). Furthermore,
severe cases of COVID-19 are characterized by cytokine storm
and acute respiratory distress syndrome (ARDS) requiring the
need for immunosuppressive therapy and mechanical ventilation
(20). The clinical evidence and immunopathology of SARS-
CoV-2 indicate that infection drives an altered immunity in
some individuals resulting in an overactive pro-inflammatory
response, which invites the opportunity to treat severe cases with
therapies capable of re-balancing the immune system.
The clinical observations and data from COVID-19 patients
support this premise. Many therapies are being investigated that
suppress the overactive immune response (21), but the impact
on immune mechanisms within these subjects is poorly defined.
Azithromycin modulates the immune response through distinct
pathways that may provide additional benefit by promoting
repair rather than full immunosuppression. Here we review
the immunomodulatory mechanisms of azithromycin along
with its clinical use as an immunomodulatory therapeutic.
We then discuss the potential impact of azithromycin on
the immune response to COVID-19, highlighting mechanisms
that potentially could provide therapeutic benefit, as well as
cautioning of possible immunosuppressive activity and off-target




Coronaviruses (CoV) are enveloped, single stranded RNA viruses
capable of infecting a range of hosts including humans, with
the novel CoV’s resulting in potentially fatal lower respiratory
tract infection (22). The three most significant CoV outbreaks
to impact humans include SARS-CoV in 2002, Middle East
Respiratory Syndrome (MERS)-CoV in 2012, and most recently
SARS-CoV-2 in 2019. The interplay between viral diversity,
host species, and underlying clinical characteristics make CoV
infections a challenge to predict, which is further compounded by
the globalization and rapid escalation to pandemic levels. SARS-
CoV-2 is an enveloped virus consisting of a lipid bilayer and four
structural proteins, including spike (S), membrane (M), envelope
(E), and nucleocapsid (N) proteins. The N protein is in complex
with single-stranded RNA on the interior of the virus, while M
and E are transmembrane proteins embedded in the lipid bilayer.
S protein is anchored in the lipid bilayer and forms a protein
corona that engages with target receptors for cellular entry (23).
Notably, SARS-CoV and SARS-CoV-2 enter cells after binding
angiotensin converting enzyme 2 (ACE2) while MERS enters
through dipeptidyl peptidase 4 (DPP4) (24). Both receptors are
expressed throughout the body and are upregulated in subjects
with comorbidities, leading to increased severity of infection in
some subjects (25, 26). These characteristics lead to additional
complications that compound the health outcomes in high risk
populations. At the time of the submission of this review, SARS-
CoV-2 has infected over 90 million people across the globe and
has contributed to over 1,950,000 deaths as the global pandemic
continues to evolve.
Stages of the Immune Response
COVID-19 has loosely been characterized to be comprised of 3
immunological stages. In the first stage, an interferon response
coordinates the control of viral replication. The second stage
is characterized by suppression of interferons by the virus,
leading to lung damage and progressive disease. Some patients
progress to a third stage of hyperinflammation coordinated by
excessive macrophage activation and coagulation (27). In later
stages, infected cells die and release virus particles along with
intracellular components that stimulate an exaggerated innate
response accompanied by large amounts of pro-inflammatory
cytokine production. Adaptive responses are then triggered late,
including CD4+ T cell cytokine release, CD8+ T cell mediated
cytotoxicity, and B cell production of antibodies. The recruitment
of inflammatory monocytes andmacrophages to the lungs lead to
a hyper-inflammatory state which contributes to the depletion of
lymphocytes and induces a cytokine storm (28, 29).
The host response is therefore implicated as a pathologic
factor of disease progression. Animal models of SARS infection
demonstrate that lung inflammation worsens after viral clearance
and peaks several days later (30). This suggests that the clinical
deterioration in late stages of the disease is likely driven not
by the virus, but by uncontrolled immune responses (31–
33). Although there remains much to be learned, it seems
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FIGURE 1 | Stages of response and progression of SARS-CoV-2 infection and the potential impact of azithromycin therapy. A hypothetical timeline of viral burden
kinetics and the associated immune response mechanisms are depicted for patients with (A) mild disease and (B) severe disease that is associated with organ
damage, hypercoagulation, and death. (A) Antiviral responses coordinated through the detection of virus via pattern recognition receptors triggers IRF signaling and
interferon production, along with pro-inflammatory signaling through NF-κB and ERK pathways. This initiates innate and adaptive immune mechanisms that limit viral
spread and leads to mild symptoms and recovery. Autophagy plays a role in pathogen elimination, but can be inhibited by the virus. (B) In some patients, viral burden
persists, possibly due to SARS-CoV-2 inhibition of IRF signaling pathways. Severe disease progresses through Stage 2 (lung damage) and Stage 3 consisting of
hyperinflammation, cytokine storm, and hypercoagulation represented here by excessive NF-κB and other inflammatory pathway activity. Rampant inflammation that
includes macrophage, neutrophil, and T lymphocyte driven pathology persists independent of viral control in Stage 3. The potential beneficial (black arrows),
detrimental (white arrows), or unknown (gray arrows) impacts of azithromycin (AZM) are depicted as defined by evidence generated in other disease models
suggesting that the drug could: increase type I/III interferon production; induce regulatory function of macrophages, blunt neutrophil influx, and decrease inflammatory
cytokine production through inhibition of NF-κB signaling and other inflammatory pathways; and impact autophagy through blocking the degradation of
autophagosomes that can impact virus infectivity, elimination, and the regulation of inflammation.
helpful to define the clinical pathology of COVID-19 in separate
stages, as the responses that are suppressed by the virus in the
early stages of infection are the very same that are involved
in the late hyperinflammatory state and are associated with
increased severity and mortality. Therefore, caution should be
taken when utilizing azithromycin or any other treatments that
modulates immunity, due to the potential to suppress antiviral
immune mechanisms. Whether immunomodulatory therapy in
an individual patient is helpful or harmful likely depends on
whether there still exists a high viral titer or whether the
individual is in the later phases of hyperinflammation.
Current Immunotherapies
Multiple clinical trials are currently being conducted that include
agents that suppress immune function, with some being used
clinically despite the lack safety or efficacy data. Many of the
inflammatory mechanisms being targeted in these trials are
associated with macrophage activation or macrophage effector
functions (34). These targets include inflammatory cytokines
such as IL-6, IFNγ, IL-1β, and TNFα; intracellular signaling
pathways including JAK-STAT signaling, TLR signaling, and the
inflammasome; and chemokines including CCR2 and CCR5 (34).
Without a thorough understanding of the immunopathology
of COVID-19, these therapies could have detrimental effects
depending on which stage of disease and what level of immune
hyperactivation a patient is currently experiencing. Poorly-timed
immunomodulation could contribute to the failure of viral
clearance, or to the inhibition of immunoregulatory mechanisms
that balance the destructive components of the response.
Initially, azithromycin was used to prevent bacterial super-
infections in early clinical studies evaluating the potential
anti-viral effects of hydroxychloroquine in patients with
COVID-19. Soon after SARS-CoV-2 reached pandemic status,
2 non-randomized studies were published, suggesting that
hydroxychloroquine in combination with azithromycin reduced
viral load in patients with COVID-19 (17, 35). As a result, the
U.S. Food and Drug Administration authorized emergency
use of hydroxychloroquine for the treatment of COVID-19,
and it was being widely used alone or in combination with
azithromycin despite limited evidence. Hydroxychloroquine is
an anti-malarial agent that inhibits acidification of endosomes
thus preventing viral replication in vitro (36). Indeed, the
initial clinical reports showed reduced viral loads with
hydroxychloroquine in patients infected with SARS-CoV-2,
an effect which was further enhanced with azithromycin (17).
However, subsequent clinical studies contradicted these findings
demonstrating no added anti-viral effects with combination
therapy, emphasizing the need for additional studies to define
any potential synergistic effects or increased risks (37). In a
retrospective cohort study conducted in 368 United States
veterans, hydroxychloroquine with or without the addition of
azithromycin showed no benefit in the treatment of patients
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hospitalized with COVID-19, and of concern, the group
receiving hydroxychloroquine alone had a significantly higher
mortality rate (38). An additional single-arm study of 11
subjects treated with hydroxychloroquine and azithromycin
reported no impact on virologic clearance (37). Subsequently, a
retrospective analysis of 1,061 patients with COVID-19 treated
with hydroxychloroquine and azithromycin in France reported
virologic cure in over 90% of the cohort within 10 days of
the initiation of therapy (39). Results from these reports are
difficult to interpret, as there is no way to factor in treatment
bias or underlying severity of cases, which could significantly
skew the reported results. At present, a high number of clinical
trials are planned or underway evaluating chloroquine or
hydroxychloroquine for the treatment of COVID-19, many
of which also include these agents in combination with
azithromycin. One such study recently published demonstrated
a reduction in mortality in patients hospitalized with COVID-19
when treated with hydroxychloroquine alone or in combination
with azithromycin (40). Due to disparate results, clearly
additional trials are needed. The potential immune targets in
response to SARS-CoV-2 infection, and the evidence suggesting
a potential impact of azithromycin for each is summarized in
Table 1.
The potential cardiotoxicity of azithromycin and other
immune-based therapies should be considered and assessed
in the ongoing clinical trials evaluating therapeutic efficacy
against SARS-CoV-2. Patients with underlying comorbidities
are at significantly higher risk of hospitalization and severe
disease, with cardiovascular pathology and its complications
among the leading causes of death in patients with COVID-
19 (67). Acute cardiac injury is commonly observed in severe
cases and is strongly associated with mortality in 19–40%
of hospitalized COVID-19 patients (31, 67, 68). In addition
to multi-organ failure and ARDS, patients that experience
cytokine storm also have a high incidence of myocardial injury
and cardiomyopathy (69, 70). Pro-inflammatory monocyte and
macrophage recruitment along with an increased production
of the chemokines MCP1 and IL-8 are associated with
mortality among COVID-19 patients (71). These changes
are reminiscent of the inflammatory response after acute
myocardial infarction (AMI) which is characterized by an
imbalance between pro- and anti-inflammatory macrophages
leading to cardiac dysfunction and impaired healing. Although
hydroxychloroquine and azithromycin in combination have
shown potential efficacy in enhancing viral clearance, patients
with COVID-19 have higher incidence of fatal arrhythmias
and heart failure, either due to pre-existing conditions or
to the infection itself. As discussed below, azithromycin
may have utility in decreasing the inflammatory mediators
associated with cytokine storm; however, because of the
drug’s association with cardiotoxicity and arrhythmia (72–76),
particularly when combined with hydroxychloroquine (77),
its use in COVID-19 patients should proceed with caution.
Future modifications in the manner in which these agents
are utilized may be required to maintain their therapeutic




Azithromycin is a macrolide antibiotic primarily used in the
treatment of upper and lower respiratory tract infections
that is effective against some Gram-positive, Gram-negative,
and atypical bacteria through binding to the 50S ribosomal
subunit in bacteria thereby inhibiting protein synthesis (78).
Azithromycin is orally bioavailable and accumulates within
cells and tissues, particularly in macrophages, to achieve tissue
concentrations that are 50-fold greater than that in plasma (79,
80). Additionally, azithromycin has a long half-life estimated
to be about 35–40 h in humans following a single 500mg dose
(78). Despite its large therapeutic window, azithromycin can
cause gastrointestinal toxicity and cardiotoxicity, including QT
prolongation and arrhythmia (81). Characterization of this off-
target effect in clinical studies led the U.S. Food and Drug
Administration to issue a warning concerning the cardiotoxicity
of azithromycin (72–76). Despite this risk being very low in
patients with no co-existing risk factors, the use of azithromycin
should be closely monitored in patients with pre-existing
cardiac problems, arrhythmias, baseline QT prolongation, and
electrolyte disturbances (73–76, 82).
Clinical Use of Azithromycin as an Immunomodulator
Azithromycin is also utilized clinically to modulate immune
responses, primarily in patients with chronic inflammatory
lung diseases. The same anti-infective dosage range of 250–
500mg was utilized in the vast majority of studies evaluating
its immunomodulatory impact. However, several of the trials
described below demonstrate that instead of daily dosing,
thrice weekly administration is also effective, likely due to
its accumulation within macrophages and long half-life (78–
80). Azithromycin therapy has been demonstrated to improve
lung function in patients with panbronchiolitis (83, 84),
and decrease the rate of pulmonary functional decline in
patients with bronchiolitis obliterans syndrome (BOS) after lung
transplantation (50, 85–87). Azithromycin therapy also has been
established in a series of randomized trials to decrease the
frequency of pulmonary exacerbations and improve quality of
life measures in patients with chronic obstructive pulmonary
disease (COPD) (88, 89). This benefit appears to be most
applicable to subsets of patients who are older and those with
more mild disease (90, 91). Trials in patients with asthma have
produced mixed results (92–95), and a recent meta-analysis
of 7 randomized controlled trials demonstrated no beneficial
clinical outcomes attributable to chronic azithromycin therapy
(96). Effectiveness in these patient populations is thought to
mainly be due to the ability of azithromycin and other macrolides
to reduce pro-inflammatory cytokine production and decrease
neutrophil influx, although the antimicrobial and antiviral effects
also likely contribute.
The vast majority of azithromycin’s evaluation and use
as an immunomodulatory therapeutic, however, has been
conducted in patients with cystic fibrosis (CF). Patients with
CF suffer from chronic lung inflammation due to immune
dysregulation and thickened mucus in the lungs caused by
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TABLE 1 | Host responses of COVID-19 and the potential immunomodulatory targets of azithromycin, along with a summary of the supporting evidence and species
investigated (m, mouse; hu, human).
COVID response Potential target Azithromycin effect and supporting evidence Species
Weakened type
I/III IFN
Type I/III IFN ↑ Upregulates in vitro production in response to rhinovirus (41–43) and Zika virus (44)
infections
hu
Cytokine Storm IL-6 ↓ Decreases in vivo concentrations in P. aeruginosa and S. pneumoniae pneumonia
(45, 46) and after AMI (47)
m
↓ Decreases serum concentrations in CF (2–6) and after influenza infection in
combination with oseltamivir (48)
hu
TNFα ↓ Decreases serum concentrations in CF (2–6) hu
↓ Decreases in vivo concentrations after SCI (49) and after AMI (47) m
IL-1 ↓ Decreases in vivo concentrations after SCI (49) and after AMI (47) m
IL-8 ↓ Decreases serum concentrations after influenza infection in combination with
oseltamivir (48), in BOS (50, 51), and in transplant recipients experiencing acute
allograft dysfunction (52)
hu




NF-κB ↓ Inhibits nuclear translocation of NF-κB subunits (7–11) m, hu
↓ Associated with decreased inflammatory cytokine production (7–9, 11, 54–56) m, hu
STAT1 ↓ Inhibits in vitro phosphorylation of STAT1, classical macrophage activation (12) m
Arg-1 ↑ Increases expression which controls production of NO and T cell proliferation
(45, 57, 58)
m
Inflammasome ↓ Decreases in vitro mRNA stability for the NLRP3 gene transcript (13) hu
Neutrophils Recruitment/influx ↓ Decreases numbers in peripheral blood and inflamed tissues in CF (59) and BOS
(50, 52)
hu
↓ Decreases influx into inflamed tissues in bacterial pneumonia (45, 60), AMI (47), and
BOS (61)
m
NET formation ↓ Decreases NET release in vitro (62) hu
IL-1β ↓ Inhibits AP-1 signaling in lungs induced by LPS administration (63) m
Lymphocytes NF-κB ↓ Inhibits in vitro NF-κB pathway in T cells (erythromycin) (64) m
mTOR pathway ↓ Suppresses CD4+ T cell activation through modification of downstream targets in
mTOR pathway (65), possibly in NK cells to decrease inflammatory cytokine
production (66)
m, hu
IL-17 ↓ Decreases lung concentration in BOS-induced lung transplant (61) m
↓ Decreases plasma concentrations after influenza infection in combination with
oseltamivir (48)
hu
Autophagy Autophagosomes ↑ Increases number and alkalinizes lysosomes in macrophages (15, 16) hu
TNFα/IFNγ ↓ Inhibits expression, thereby reducing autophagosome clearance (15) hu
mutation of the cystic fibrosis transmembrane conductance
regulator (CFTR) gene that impacts proper chloride ion transport
(97). A series of randomized, placebo-controlled clinical trials
established the short-term efficacy and safety of longitudinal
azithromycin therapy in patients with CF (2–6). Additionally,
a meta-analysis of these trials was conducted comparing
azithromycin therapy against placebo by including 959 patients
spanning a wide age range (98). Beneficial effects included
significant improvement in pulmonary function, a reduced
frequency of exacerbations, a decrease in hospitalizations, and
an improved quality of life. Recently, the first long-term study
of azithromycin therapy in patients with CF was published (99).
This observational analysis showed that azithromycin reduced
pulmonary functional decline over a 3 year period, with a
significantly more pronounced effect in patients chronically
infected with Pseudomonas aeruginosa, the organism responsible
for the highest incidence of acute pulmonary exacerbation in
these patients (99).
These clinical studies demonstrated that azithromycin blunts
neutrophil influx into the lungs, an effect associated with
decreases in IL-8, neutrophil elastase, and C-reactive protein
concentrations (3, 59). Despite the immune modulation that
could have led to a decreased ability to effectively respond
to pathogen invasion, and although long-term antibiotic use
could contribute to antimicrobial resistance and other issues
of collateral damage, the chronic use of azithromycin reduced
infection risk and the need for antibiotics (98). Patients with
CF treated with azithromycin had significantly lower rates of
Staphylococcus aureus and P. aeruginosa infections, and with
the exception that use of the drug was associated with a higher
number of infections with macrolide-resistant S. aureus, the risk
for acquiring all other infections was not impacted (98).
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Immunomodulatory Mechanisms of
Azithromycin
Antiviral Effects of Azithromycin
The impact that azithromycin exposure exerts upon viral
replication and survival has been demonstrated for a number
of viral pathogens (41, 100). Antiviral effects are most likely
due not to the direct binding of azithromycin to viral targets,
but alterations in mammalian cellular functions that disrupt
the mechanisms by which viruses replicate, spread, and survive.
One hypothesis of the drug’s antiviral effect is through its
ability to increase the pH in endosomes (101). Azithromycin
is a weak base and accumulates in endosomal vesicles and
lysosomes, which could increase the pH and block endocytosis
and viral shedding (101). Additionally, azithromycin blocks
internalization of influenza virus by host cells during early
phases of infection in vitro—this was translated to a mouse
model of influenza infection in which azithromycin reduced viral
loads after a single intranasal administration (102). Similarly,
there exists the potential for azithromycin to inhibit the entry
of SARS-CoV-2 by interfering with the binding of the virus
to its receptor, ACE2, but this has only been proposed using
quantum mechanical energetics modeling (103). Additionally,
the inhibition of autophagosome clearance by azithromycin in
human cells discussed below could impact viral disposition inside
infected cells (15).
Azithromycin can also exert antiviral effects through the
up-regulation of interferon production. In a study using
normal bronchial epithelial cells, azithromycin significantly
increased rhinovirus 1B- and rhinovirus 16-induced interferons
and interferon-stimulated gene mRNA expression and protein
production (41). Replication and release of each of the
rhinoviruses tested was significantly reduced at biologically
achievable concentrations of azithromycin after 24 and 48 h
of culture (41). Similar findings were reported using primary
bronchial epithelial cells from children with CF and from adults
with COPD (42, 43). Azithromycin augmented the expression
of type I and III interferons, along with retinoic-inducible gene
I (RIG-I)-like helicase, a viral pattern recognition receptor that
leads to interferon signaling, in bronchial epithelial cells isolated
fromCOPD patients infected with rhinovirus 16 (43). Rhinovirus
infections are a primary cause of virally-induced respiratory
exacerbations in patients with COPD and CF (104, 105),
and therefore longitudinal azithromycin therapy may impact
exacerbation frequency through this mechanism. Additionally,
azithromycin was shown to attenuate the replication of Zika virus
by the same mechanism associated with the up-regulation of the
production of host type I and III interferons (44).
Azithromycin Inhibits Inflammatory Cell Signaling
The anti-inflammatory properties of the macrolide antibiotics
were first investigated by exploring the impact of erythromycin
on the suppression of cytokine production (106, 107). This
led to studies examining the ability of macrolides, including
azithromycin, to suppress the activation of the inflammatory
transcription factor NF-κB. These early studies demonstrated
that azithromycin prevents the nuclear translocation of the
activated subunits of NF-κB thereby reducing the up-regulation
of pro-inflammatory gene expression (7–11). These data led
to the evaluation of the impact of azithromycin upon other
aspects of inflammatory cell signaling including suppression of
the inflammasome, inhibition of phospholipase-A2 (PLA2), and
the regulation of autophagy (13–15, 108). Decreases in NF-κB
DNA binding were mechanistically linked to the suppressed
induction of pro-inflammatory genes and cytokine production
in different murine and in vitro models of inflammatory
and infectious diseases (7–9, 11, 54–56). The impact of
azithromycin on cytokine and chemokine production impacts
downstream inflammatory processes including a reduction in
immune cell infiltration, alterations in epithelial cell barrier
function, and decreases in endothelial cell expression of adhesion
molecules (11).
Erythromycin was first demonstrated to inhibit NF-κB DNA
binding in human Jurkat T cells (64), and to inhibit the DNA
binding of both NF-κB and activator protein (AP)-1 in human
bronchial epithelial cell lines stimulated by phorbol esters (109).
These mechanisms were subsequently demonstrated in human
monocytes stimulated with lipopolysaccharide (LPS) using the
macrolide clarithromycin (110), and then with azithromycin
in CF- and non-CF human bronchial epithelial cell lines (7,
111). Additionally, a study using cells isolated from the tracheal
aspirates of neonates demonstrated that the decrease in NF-
κB activation (and subsequent IL-6 and IL-8 production) by
azithromycin is associated with inhibition of the degradation of
IκBα, the protein that prohibits the active subunits of NF-κB from
translocating into the nucleus (112). These effects are associated
with a significant reduction in inflammatory cell infiltration into
infected lungs, and a profound decrease in pro-inflammatory
cytokine concentrations in the alveolar space.
Azithromycin also inhibits LPS-induced expression of PLA2.
This enzyme is involved in cell signaling processes that produce
arachidonic acid and eicosanoids (113), and also induces cytokine
and chemokine production in macrophages, neutrophils, and
endothelial cells (114). In a mouse macrophage cell line
stimulated with LPS, azithromycin decreased eicosanoid and
arachidonic acid production, along with IL-6 and prostaglandin
E2 (108). From this work and additional results that demonstrate
macrolides bind to membrane-bound phospholipids, the authors
hypothesized that decreases in PLA2 substrate availability
contributes to the anti-inflammatory mechanism of these agents
(108, 115).
Additionally, several groups have studied the impact of
azithromycin on ERK1/2 and inflammasome function. AP-1
activity is regulated in part by ERK1/2 signaling molecules
(116), and binding of AP-1 to the enhancer region of the IL-
1β gene is important for its expression (117). While NF-κB
activation is necessary for the gene transcription of inactive
forms of inflammatory cytokines such as pro-IL-1β, cleavage
by the caspase-1 inflammasome is required for activation
(118). Azithromycin was reported to inhibit AP-1 signaling in
neutrophils isolated from the lungs of mice induced by LPS
administration, which thereby decreased IL-1β concentrations
(63). This effect on the inflammasome is also associated with the
drug’s ability to decrease the mRNA stability for the NLRP3 gene
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transcript, a sensing component of the NALP3 inflammasome,
in human monocytes (13). Although the interplay between
these signaling pathways is clearly impacted by azithromycin,
the primary mechanism of action and target of azithromycin
remain undiscovered.
Azithromycin Alters Macrophage Polarization
Studies of the immunomodulatory properties of azithromycin
were extended to define the agent’s impact on macrophage
polarization. Macrophages are polarized to distinct functional
phenotypes via signaling through two separate pathways.
Classical, or M1 macrophages are activated by TNFα or
IFNγ when stimulated by non-self foreign antigens, and
through signaling via STAT1 and NF-κB pathways induce an
inflammatory gene expression pattern (119, 120). Conversely,
alternatively (M2)-polarized macrophages are activated by IL-
4 or IL-13, are involved in Th2-type inflammatory responses,
and function to orchestrate remodeling and repair and to
regulate inflammation (121, 122). While the M1/M2macrophage
polarization paradigm oversimplifies the dynamic and complex
macrophage activation landscape (123), it is a useful framework
for comparisons across different disease states, treatments, and
between in vivo and in vitro systems. Experiments using the
murine macrophage cell line J774 demonstrate that azithromycin
polarizes macrophages to an M2 alternative-like phenotype
in vitro (57). In macrophages polarized to an M1 phenotype
with IFNγ and LPS, azithromycin inhibited pro-inflammatory
cytokine expression (including IL-12 and IL-6) and shifted
surface receptor expression to that typically observed in
alternatively-activated macrophages. Additionally, expression of
the M1-effector protein iNOS was decreased and expression
of the M2-effector protein arginase was increased by the drug
(57). The effect of azithromycin on macrophage polarization
has also been demonstrated in human monocytes stimulated to
undergo classical activation in vitro (9). Azithromycin inhibited
production of the M1 macrophage proteins CCR7 and IL-12p70,
but in this study TNFα and IL-6 production were unaffected. The
drug also increased M2 protein expression including IL-10 and
CCL18 in this model (9).
This was followed up by studies investigating macrophage
polarization by azithromycin in mice infected with P. aeruginosa.
Regulatory macrophage functions were induced by azithromycin
treatment early after infection with P. aeruginosa-laden agarose
beads, a model that causes a prolonged, sub-chronic pneumonia
(124). This led to a reduction in neutrophil influx, decreased
inflammation, and reduced fibrotic lung damage that correlated
with improved morbidity and survival (45). Macrophage
polarization toward a more regulatory response was reflected
in that M2-associated surface expression of mannose receptor
(MR) was increased, as was the production of arginase (45).
Additionally, infiltrating monocytes and macrophages in the
azithromycin-treated mice exhibited greater production of
IL-10 and significantly lower production of TNFα, CCL2,
and IL-6. Importantly, the clearance of P. aeruginosa, an
organism that is not susceptible to the drug, was not
altered by azithromycin treatment. This work demonstrates
that modulation of neutrophil and inflammatory macrophage-
driven inflammation can be regulated by azithromycin without
mitigating the ability of the immune response to evoke bacterial
clearance (45). These results are reflective of the clinical practice
of longitudinal azithromycin therapy in patients with CF, in
whom P. aeruginosa often drives exacerbations and pulmonary
functional decline (2–4).
A recent study shed additional light on the mechanism by
which azithromycin polarizes macrophages to a regulatory
phenotype (12). Incubation of a murine macrophage cell line
or primary murine macrophages with azithromycin was found
to increase the overall expression of IκB kinase (IKKβ), a
molecule involved in signaling to NF-κB activation. When cells
were stimulated with IFNγ and LPS, azithromycin treatment
increased the phosphorylation of IKKβ despite a reduction
in the subsequent signaling resulting in inhibition of NF-
κB translocation into the nucleus (12). The kinase activity
of IKKβ was inhibited by azithromycin and represents a
potential mechanism for these effects. Because of a previous
report demonstrating that the over-expression of IKKβ
can inhibit STAT-1 signaling (the pathway responsible for
classical macrophage activation in the presence of IFNγ) (46),
investigators then explored this connection and found that
azithromycin inhibited the phosphorylation of STAT-1, an effect
that was dependent upon IKKβ. Induction of the M2 protein
arginase was also dependent on this cross-talk, as IKKβ inhibitors
reversed the ability of azithromycin to induce arginase activity
(12). Likewise, macrophage-specific deletion of IKKβ conferred
resistance to Group B Streptococcus infection in mice, an effect
that was associated with increased expression of inflammatory
molecules including IL-12, iNOS, and MHCII (46). This work
provides a possible mechanistic link between NF-κB signaling
inhibition and macrophage polarization by the drug.
Macrophage polarization with azithromycin has also recently
been demonstrated to be effective in reducing inflammatory
injury stemming from acute myocardial infarction (AMI) (47,
125) and spinal cord injury (126). Myocardial and spinal
cord injury are exacerbated by the recruitment of monocytes,
macrophages, and neutrophils in response to tissue damage
(127, 128). In the case of AMI, neutrophil and inflammatory
macrophage infiltration is associated with ineffective tissue
remodeling and the development of heart failure (129, 130).
In a mouse model of permanent coronary artery ligation,
azithromycin treatment polarized the macrophage response
to an M2-dominant phenotype and blunted the influx of
neutrophils into the heart after AMI, thereby decreasing scar
size, cardiac remodeling, and mortality (47, 125). Similarly,
azithromycin treatment after SCI in mice was shown to
increase markers of regulatory macrophage activity, improve
locomotor recovery, and reduce SCI lesion pathology (49,
126, 131). In each of these conditions, mice treated with
azithromycin had significant decreases in pro-inflammatory
macrophage effectors including TNFα, IL-6, IL-1β, and MCP1,
and an increase in M2-associated expression of CD206
and TGFβ. This work is supported by gene expression
data generated using in vitro systems that broadly captures
the immunomodulatory shift in macrophage polarization by
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azithromycin (49). Similar observations using azithromycin
have also been reported in other neuroinflammatory conditions
including stroke and retinal ischemia/reperfusion injury (132,
133).
Clinical studies also reflect the impact of azithromycin therapy
on macrophage polarization in patients with inflammatory
diseases. Azithromycin administration to patients with COPD
led to an increase in expression of the M2-associated proteinMR,
along with reduced airway inflammatory cytokine concentrations
and improved phagocytic function of alveolar macrophages
(134). And in a study of patients with systemic lupus
erythematosus, in addition to causing a reduction of pro-
inflammatory cytokine production, azithromycin increased the
gene expression of the M2 macrophage effectors arginase-1,
Fizz-1, and IL-10 (135). While preclinical and clinical studies
of the therapeutic utility of alternative macrophage polarization
in conditions with inflammatory pathology show promise,
additional investigation is necessary in order to determine which
regulatory aspects of macrophage function are beneficial.
Azithromycin Directly and Indirectly Impacts
Neutrophils
Themechanisms described above demonstrate that azithromycin
reduces damaging aspects of neutrophil-driven responses
through its impact on the coordination of inflammation
and repair by macrophages. Additionally, azithromycin can
directly affect neutrophil function. Neutrophils, primed by
damage-associated molecular patterns and other signals, play
important, though often destructive, roles in airway diseases
including CF (136, 137), asthma (138), COPD (139), and
ARDS (140). Azithromycin accumulates in neutrophils and
has an extremely long half-life in these cells (51, 141). In
vitro azithromycin exposure of human neutrophils modulates
neutrophil extracellular trap (NET) release (62), and a recent
report demonstrated that the macrolide erythromycin decreases
airway NET formation in mice (142). Azithromycin has also
been shown in human clinical studies to decrease IL-8 release
and neutrophil airway infiltration, cause degranulation and
degradation of extracellular myeloperoxidase, and reduce
neutrophil oxidative burst (50, 51). Macrolides also decrease
production of leukotriene B4 (LTB4) (143), a potent neutrophil
chemoattractant that stimulates neutrophil IL-8 release (144).
Azithromycin’s Impact on Lymphocytes
While the alteration of cytokine production of myeloid cells can
impact adaptive immunity in many ways, less is known about
the direct effects of azithromycin and the other macrolides on
lymphocyte function. Early studies of the immunomodulatory
properties of erythromycin demonstrated that NF-κB inhibition
also occurs in T cells when stimulated in vitro (64). Azithromycin
has also been shown to suppress T cell activation through
modification of the mTOR signaling pathway (65). A direct
effect of azithromycin on T cells was characterized in a study
of 11 subjects with COPD. Azithromycin therapy reduced
granzyme B production in the airways, an effect that was
confirmed in vitro to be suppressed in both CD4+ and
CD8+ T cells (145). Macrolides also impact the Th1/Th2
cytokine balance, although reports are conflicting as to whether
the shift is more toward the production of IFNγ or IL-
4. In a study of patients with CF, clarithromycin therapy
skewed the response toward that of Th1 dominance (146),
and a study using ex vivo stimulation of primary mononuclear
cells exposed to clarithromycin demonstrated an increase
in the number of T cells producing IFNγ (147). However,
in a similar study examining mitogen-stimulated human T
cells in vitro, clarithromycin inhibited IFNγ production to
a greater extent than it inhibited the production of IL-
4 (66).
Little has been investigated in terms of a direct effect of
azithromycin on natural killer (NK) cells. NK cells are innate
effector lymphocytes that are important in the response to
viral infections. In vitro studies demonstrate that azithromycin
decreases perforin production in primary human NK cells as
well as the production of IFNγ and TNFα in an NK cell
line (148). Although the impact of azithromycin on NK cell
disposition during infection remains to be studied, because
the mTOR pathway governs NK cell activation as it does in
T cells, azithromycin may have a significant impact on the
ability of NK cells to produce cytokines or other functions that
contribute to either the inflammatory response or the clearance
of pathogens.
Azithromycin also can dampen the lymphocytic airway
inflammation associated with BOS after lung transplantation. IL-
17 is important in the pathophysiology of allograft rejection,
during which production of the cytokine by CD8+ T cells drives
a lymphocytic airway inflammation (149, 150). Compounding
this problem is the fact that regulatory T cells, which
typically inhibit IL-17 production, are often reduced due
to the immunosuppressive agents used to prevent rejection
in patients who have undergone solid organ transplantation
(151). In a study of 15 lung transplant recipients experiencing
acute allograft dysfunction, azithromycin therapy decreased
neutrophil and eosinophil influx into the lungs, blunted
cytokine and chemokine production including IL-1β, IL-8,
and CXCL10, and significantly controlled airway inflammation
(52). While sputum concentrations of IL-17 were not affected,
the authors concluded that azithromycin decreased IL-17+ T
cell-mediated airway inflammation (52). Similar results were
obtained in a separate study of 17 lung transplant patients
with BOS, where azithromycin decreased neutrophil influx
which was associated with decreased IL-8 mRNA expression,
but no change in IL-17 mRNA expression was noted (50).
This has additionally been recapitulated in mice subjected to
IL-17 administration directly into the lungs (152), and in
primary human airway smooth muscle cells in culture, in
which azithromycin blocked IL-17-induced IL-8 production
(53). Conversely, in an animal model of BOS induced by
lung transplantation, azithromycin did significantly reduce the
lung concentration of IL-17 as well as the number of IL-
17-producing T cells (61). Additionally, a randomized clinical
study evaluating the impact of azithromycin treatment in
combination with oseltamivir for the treatment of influenza
demonstrated that the addition of azithromycin decreased
plasma concentrations of IL-17, IL-6, IL-8, CXCL9, and CRP
Frontiers in Immunology | www.frontiersin.org 8 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
(48). This was associated with faster symptomatic resolution,
yet there was no change in viral clearance rates (48). Taken
together, these studies suggest that azithromycin primarily affects
T cell-mediated responses through an impact on downstream
effectors, however a direct impact on IL-17 production is
also probable.
When azithromycin polarizes macrophages to an alternative-
like phenotype, this includes a dramatic increase in the
production of the M2 protein arginase-1 (45, 57). Arginase-1
expression is induced in macrophages, neutrophils, and other
immune cells where it competes with iNOS thereby regulating
NO generation and limiting NO-mediated inflammatory injury
(153). Additionally, arginase-1 can also immunoregulate by
controlling T cell activation and proliferation (154, 155).
T cells are highly sensitive to the localized depletion of
arginine and other amino acids essential for their proliferation
and function (154, 156, 157). Arginase-mediated depletion of
arginine has been characterized to impact T cell-mediated
responses in a variety of infection models and inflammatory
processes including trauma, asthma, glomerulonephritis, and
malignancy (158). In the case of viral infections, both
arginase and NO can be either helpful or harmful through
enhancement or inhibition of viral clearance, or through
enhancement of the associated immunopathology (159). Control
of T cell disposition through increased arginase activity
represents an additional mechanism by which azithromycin
could impact adaptive immunity, however more work in this area
is needed.
Azithromycin Inhibits Autophagosome Flux
Autophagy, the catabolic process that regulates the elimination
of defective intracellular proteins and components (160), also
plays a complex role in both pathogen elimination and the
regulation of inflammation (161). Azithromycin, at therapeutic
concentrations, was demonstrated to increase the number of
autophagosomes in macrophages (15, 16). Molecular studies
in primary human macrophages determined that this occurs
through the inhibition of autophagosome degradation, rather
than by causing an increase in their synthesis (15). Azithromycin
accomplishes this by inhibiting lysosomal acidification which
thereby inhibits autophagosome clearance (15). Compelling
evidence reveals that the dysregulated inflammatory state of
myeloid cells with CFTRmutation is tied to defects in autophagy.
Restoring efficient autophagy in mice with the F508del mutation
in CFTR, the most common mutation that produces severe
disease in CF, restores control of excessive production of pro-
inflammatory cytokines by macrophages typically observed as a
result of CFTR dysfunction (162–164). This discovery led to 2
clinical trials in patients with CF with F508del-CFTR mutations
in which the restoration of autophagy resulted in the suppression
of pro-inflammatory cytokine production and improved lung
function (165, 166). However, inhibition of autophagy flux
has also been linked to decreases in pathogen elimination
(15, 167). While considerable overlap between autophagy and
inflammation has been characterized, as autophagy contributes to
both host defense and control of associated inflammatory injury
(167, 168), the impact of azithromycin at this nexus remains to
be studied.
IMMUNE PATHOLOGY OF COVID-19 AND
POTENTIAL IMPACT OF AZITHROMYCIN
Antiviral Immune Response (Stage 1)
Upon exposure to CoV, the innate immune response is activated
through standard anti-viral signaling cascades initiated through
toll-like receptors (TLR), NOD-like receptors (NLR), and
others, which result in signaling through pathways to activate
downstream transcription factors including IRF3 and NF-κB
(169). Typically, innate immune cells detect viral infection
through these viral pattern recognition receptors which triggers
the expression of type I interferon and other pro-inflammatory
cytokines including IL-1, TNFα, and IL-6 (170, 171). The
expression of type I interferon through IRF3 signaling is critical
for the clearance of viral infections (172). The resulting influx
of phagocytes to the site of infection initiates antigen processing
and presentation which elicits both CD4+ (helper T cells) and
CD8+ (cytotoxic T cells) responses in subjects infected with
SARS-CoV or SARS-CoV-2. Coronaviruses are characterized
by a phospholipid bilayer decorated with envelope proteins
including spike protein (S), an internal nucleoprotein (N) in
complex with RNA, and others (173). Durable and persistent
antibody responses to the S protein have been reported in
SARS-CoV infection (174) and MERS-CoV infection (175), with
similar results observed thus far for SARS-CoV-2 (176–178). The
receptor binding domain of the S1 spike protein is responsible for
binding to ACE2, and is the likely target of eventual neutralizing
antibody responses (179–181). These data indicate that both
cellular and humoral immune responses are initiated to fight
the virus.
Some patients infected with novel coronaviruses, however,
fail to mount a robust initial response. This is thought to be
due to evasive mechanisms of SARS-CoV, MERS, and SARS-
CoV-2 that suppress early type I interferon production. SARS-
CoV suppresses the activation of TNF receptor-associated factors
(TRAF) 3 and 6, which suppresses early type I interferons and
pro-inflammatory effectors including IL-6 and TNFα (182). The
virus can also inhibit STAT transcription factor phosphorylation
and thereby counteract type I IFN signaling (171). Notably, the
N protein of SARS-CoV serves as an interferon antagonist and
downregulates JAK-STAT signaling in infected cells (183). These
mechanisms allow the novel coronaviruses to suppress immune
responses thereby allowing proliferation of infection in larger
numbers of pulmonary epithelial cells.
Additionally, activated CD8+ cytotoxic T lymphocytes and
NK cells are important for viral clearance, and both of these
cell types have been found to be significantly decreased in
patients with more severe COVID-19 (184, 185). Although the
mechanism is unknown, this is likely due to virus-induced
apoptosis and decreased T cell priming and activation secondary
to impaired dendritic cell migration found with SARS-CoV
infection (68, 186, 187). These factors likely contribute to the
propagation of the virus in patients that advance to severe disease.
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The established ability of azithromycin to up-regulate the
production of type I interferons in response to rhinovirus
and Zika virus provides a foundation for investigating this
mechanism in SARS-CoV-2 infection (41–44). Interferon λ1 (a
type III interferon) is theorized to play a significant role in
response to COVID-19 infection in humans by reducing viral
load and preventing organ damage by preventing cytokine storm
and the resulting tissue injury (188, 189). If azithromycin can
induce the expression of interferon λ1, the drug could help
augment interferon response to COVID-19 infection, improving
viral clearance and reducing the potential for certain patients
to progress to severe disease. However, caution should be used
due to the possibility of suppressing other aspects of innate and
adaptive immunity.
Pathologic Inflammation (Stages 2 and 3)
Overview
The pathologic drivers of disease in patients infected with SARS-
CoV-2 are not completely understood, but it is clear that severe
disease is not only related to viral load. The dysregulated,
excessive inflammatory response is thought to be a major driver
of disease severity and death in patients with COVID-19 (27–
29, 190). Patients with severe disease have high peripheral
blood concentrations of pro-inflammatory cytokines, marked
lymphopenia, and infiltration of inflammatory monocytes and
macrophages in tissues throughout the body including the lungs,
secondary lymphoid tissues, and the heart (191, 192). Increased
numbers of neutrophils, decreased numbers of lymphocytes,
and increased concentrations of serum inflammatory proteins
including cytokines and chemokines have all been associated
with worsened outcomes and death (71, 185, 193, 194). A
recent report thoroughly characterized the gene expression
associated with SARS-CoV-2 in human lung-derived epithelial
cell lines, primary cultured human bronchial epithelial cells,
infected ferrets, and COVID-19 patients (18). Compared to
SARS-CoV and other viral infections, SARS-CoV-2 induces
a unique response characterized by a paucity of type I and
III interferon production and dramatic inflammatory cytokine
and chemokine secretion that is independent of viral burden.
By day 7 post-infection in ferrets, despite low virus levels,
the transcription of cytokines and chemokines continues to
expand (18). To support this, the addition of type I interferon
to the culture of a bronchial epithelial cell line induced a
dramatic reduction in viral replication, yet antagonism of
type I interferon signaling by ruxolitinib had little effect on
the production of inflammatory mediators (18). This suggests
that the production of cytokines and chemokines induced by
SARS-CoV-2 is independent of interferon-governed responses.
Although much remains to be learned, the role of innate and
adaptive immune cells in the resultant inflammatory pathology
have been partially characterized. The contribution of the major
immune cell populations, and the evidence of azithromycin’s
potential impact on each, are described below and depicted in
Figure 2.
Macrophages
Pathologic inflammation in patients infected with novel
coronaviruses is driven by high numbers of neutrophils,
monocytes, and macrophages in the airways (185). Common
features of the previous novel coronavirus outbreaks included
dramatic inflammatory cell infiltration into the lungs leading to
acute pulmonary injury and ARDS (195). Data from SARS-CoV
andMERS outbreaks that show increased numbers of neutrophils
and inflammatory monocytes in the airways of severely ill
patients (196, 197). Likewise, previous studies also show that
SARS-CoV infected patients that require intensive care have high
plasma concentrations of CXCL10, CCL2, MIP1α, and TNFα, all
of which are commonly produced by inflammatory myeloid cells
(198). Similarly, most of the cells infiltrating the lungs in patients
with severe COVID-19 are activated inflammatorymonocyte and
macrophages which produce pro-inflammatory cytokines and
chemokines and activate coagulation (29, 199–202). Although
macrophages serve as a front-line defense against invasive
pathogens through the initiation and coordination of immune
responses, they also regulate aspects of inflammation that are
damaging to host tissues and promote remodeling and repair.
Single-cell RNA sequencing of lung bronchoalveolar immune
cells in patients with SARS-CoV-2 infection indicate that
patients with severe disease, despite an increased myeloid cell
percentage in the airways, have a depletion of resident alveolar
macrophages, which typically serve a regulatory function, and
an increased proportion of inflammatory monocyte-derived
macrophages (203). Azithromycin’s ability to promote regulatory
macrophage characteristics could potentially restore the balance
of inflammatory and regulatory macrophage phenotypes that are
misaligned in patients with severe COVID-19.
The role of regulatory macrophage functions in response to
SARS-CoV-2 is not well-understood, although data is beginning
to emerge. A subset of macrophages from COVID-19 patients
has been described as expressing a gene signature associated
with tissue repair (203). Whether these functions are helpful, or
whether they contribute to the promotion of fibrotic lung injury
is not yet known. However, in a study of non-human primates,
macaques acutely infected with SARS-CoV-2 demonstrated
macrophage activation that included both pro-inflammatory and
repair characteristics (204). The presence of anti-spike IgG prior
to viral clearance decreased the regulatory aspects of macrophage
polarization and promoted MCP1 and IL-8 production along
with exaggerated monocyte recruitment to the lungs. This led
to heightened lung injury and worsened outcomes, suggesting
that the regulatory function of macrophages may be important
in suppressing fulminant inflammation (204). If this is the case,
the ability of azithromycin to promote the regulatory functions
of macrophages may be beneficial in COVID-19 patients
experiencing the detrimental aspects of myeloid cell-driven
hyper-inflammation. In addition to inhibiting the production
of inflammatory cytokines and chemokines, azithromycin
promotes regulatory aspects of macrophage function including
the production of IL-10, TGF-β, and arginase. As discussed
above however, the work characterizing macrophage polarization
by azithromycin has not been explored in the setting of
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FIGURE 2 | Potential effects of azithromycin on immune cells that contribute to hyperinflammation in COVID-19. The response to pulmonary infection with
SARS-CoV-2 is characterized by a blunted Type I/II IFN response, which could possibly be improved by azithromycin (AZM). Macrophages are implicated in the
coordination of the exaggerated inflammatory response that can lead to lung damage, cytokine storm, and increased morbidity. Azithromycin has been demonstrated
in other models to inhibit signaling mechanisms in inflammatory macrophages including NF-κB nuclear translocation, STAT1 phosphorylation, and inflammasome
activation that all contribute to pro-inflammatory mediator production including iNOS, cytokines, and chemokines. Neutrophil influx is inhibited by azithromycin, likely
through impacting chemokine production and through direct inhibition of AP-1 signaling, leading to decreases in NET formation and production of IL-1β. Proliferation
of activated T lymphocytes can be blunted by azithromycin through inhibition of mTOR signaling, as well as through increased macrophage production of arginase-1
(which thereby depletes arginine which is required for T cell proliferation). Consequently, T cell and NK cell production of inflammatory cytokines including GM-CSF,
IFNγ, TNFα, and IL-17 would be decreased. Therefore, within this theoretical model lies the potential for azithromycin to enhance antiviral effects, blunt harmful
hyperinflammation that leads to cytokine storm, or conversely inhibit desirable immunologic effects, depending on the phase of the antiviral response. Red inhibitory
lines depict possible targets of azithromycin during COVID-19, and red arrows indicate resultant increases or decreases in the production of mediators of
inflammation. Figure was created using https://biorender.com/.
a viral infection. Because the immunopathology is driven
by inflammatory signaling pathways that include NF-κB,
azithromycin’s impact onmacrophage polarization in COVID-19
is a reasonable hypothesis to explore.
However, animal studies of SARS-CoV demonstrate that
M2 polarization and increased arginase-1 activity could be
detrimental. In a mouse model of SARS-CoV infection,
investigators demonstrated that alternatively activated
macrophages were responsible for enhancing the pulmonary
pathology (58). Previous studies by this group demonstrated that
STAT1, a key signaling protein responsible for inflammatory
macrophage responses, was necessary to control viral spread
when infected with human SARS-CoV (205). SARS-CoV
infection of mice lacking hematopoietic STAT-1 expression were
shown to have greater morbidity and lung pathology, which was
associated with the activation of M2 macrophages (58). To test
whether the M2 macrophages were responsible for the enhanced
pathogenesis, the authors generated STAT-1/STAT-6 double
knockout mice, as STAT-6 drives M2 macrophage activation.
With these mice, which did not mount an M2 macrophage
response after infection, the extent of pulmonary pathology was
normalized (58). Additionally, a separate group demonstrated
Frontiers in Immunology | www.frontiersin.org 11 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
that SARS-CoV infection inmice induces an immunosuppressive
alveolar macrophage population that inhibits antiviral T cell
responses (206). Therefore, M2 macrophage polarization with
azithromycin, which may decrease inflammatory cytokine
production and arginase-1 expression thereby regulating other
damaging aspects of inflammation, could also be detrimental in
patients infected with novel coronaviruses. Future investigation
of the complex interplay between these cell types will be
necessary in order to determine which therapeutic targets, and
in what circumstances, treatment with azithromycin could
be beneficial.
The autophagy-lysosomal system plays a central role
during infection with SARS-CoV (207, 208). However, it is
unknown whether the induction of autophagy may be beneficial
to patients infected with SARS-CoV-2 (209). Autophagy is
involved in viral entry, viral clearance, and both initiation and
regulation of inflammatory pathways (167). There is conflicting
evidence as to whether CoVs inhibit autophagy. Therefore,
the inhibition of autophagosome flux by azithromycin could
be beneficial in terms of direct antiviral effects, and could
counteract the hyperinflammation associated with dysregulated
pro-inflammatory cytokine release (15). Chloroquine, an
immunotherapeutic agent being studied for its efficacy against
SARS-CoV-2, also inhibits autophagic flux by inhibiting
autophagosome-lysosome fusion (210). However, its mechanism
of action in the case of SARS-CoV may not be due to this
effect, but rather due to chloroquine’s inhibition of endosomal
acidification, thereby preventing cellular entry (36). Although
the induction of autophagy, or the inhibition of autophagosome
flux, could impact SARS-CoV-2 infection through multiple
effects, a better understanding of the interaction between host
mechanisms and the virus are needed in order to properly
evaluate these targets.
Neutrophils
The ability of azithromycin to blunt macrophage-driven
neutrophil influx lends promise to the drug’s potential impact on
patients infected with SARS-CoV-2. Recent reports concerning
the immune response in COVID-19 have characterized extensive
neutrophil infiltration into diseased lung tissue as well as
significant evidence of NET release in the serum (211, 212).Much
like NETosis observed in lungs of ARDS patients subsequent
to pneumonia or sepsis, NET release in the lungs of COVID-
19 patients may play a pathologic role (213). NETs have also
been reported to promote intravascular coagulation (214), and
although whether this impacts mechanisms that contribute
to hypercoagulation and stroke that have been reported as
clinical complications associated with COVID-19 remains to be
determined (215, 216). Despite the usefulness of azithromycin
in these neutrophilic airway diseases, and its direct inhibition
of NET production, care should be taken when azithromycin
is administered under the suspicion of viral infection. Rodent
studies have found that neutrophils are protective during
infection with SARS-CoV (217) and severe influenza (218, 219),
and also help to prevent bacterial pneumonia secondary to
influenza infection (220). Therefore, severely limiting neutrophil
infiltration and activity in the airways may have some undesirable
consequences, and the efficacy of such a therapy will likely
depend on the individual patient circumstances.
Lymphocytes
Despite their depletion in COVID-19, lymphocytes appear to
contribute to the macrophage hyperactivation that leads to
the development of cytokine storm, a state in which pro-
inflammatory cytokines drive excessive, damaging inflammation.
Systemic cytokine profiles in patients with COVID-19 are similar
to those observed in cytokine release syndromes often driven
by macrophages, including high levels of circulating IL-6, IL-17,
TNFα, CCL2, and CXCL10. These cytokines will induce T cells
and NK cells to produce additional cytokines including GM-CSF
and IFNγ. An abundance of peripheral blood CD14+CD16+
monocytes has also been described in COVID-19 patients with
severe disease to produce high amounts of IL-6 (199, 221).
In patients with severe COVID-19, this abundance was also
associated with the presence of CD8+ T cells that produced high
amounts of GM-CSF, which can further induce IL-6 production
(221). Likewise, pathogenic CD4+ T cells producing both IFNγ
and GM-CSF were exclusively found in patients with severe
disease, indicating their likely role in the hyperinflammatory
response (221). Additionally, results from a recent in-depth
analysis of NK cells isolated from patients with COVID-19
revealed that despite low NK cell numbers in these patients,
the NK cell phenotype associated with severe disease was
robustly activated and associated with increased IL-6 levels
(222). However, in a separate report, the presence of IL-6-
producing macrophages was associated with severe lymphocyte
depletion in the spleen and lymph nodes in patients with severe
COVID-19 (223). Additionally, highlighting the complexity of
these interactions, expression of genes and surface proteins
associated with T cell and NK cell exhaustion has also been
associated with severe disease (184, 221). As discussed above,
modulating the immune response with azithromycin consistently
results in decreased production of IL-6 across both infection-
and non-infection-driven pathology. The drug’s impact on IL-6
production could be a key factor in its potential efficacy, although
the direct impact on NK cell production of IL-6 by azithromycin
has not been studied.
The severity of disease for MERS-CoV, SARS-CoV, and SARS-
CoV-2 has also been shown to positively correlate with levels of
IL-17 and other Th17 cell-related pro-inflammatory cytokines
(186, 224). A recent study of 39 patients with COVID-19
demonstrated that although CD4+ and CD8+ T cell numbers
in circulation were low, the cells produced higher amounts
of IL-17 when stimulated in vitro, which links lymphopenia
to hyperinflammation (225). As discussed above, azithromycin
may target T cells directly by inhibiting intracellular signaling
pathways and expression of T cell cytokines including IL-17,
although most of the effects on these immune mechanisms
seem to center on the downstream effectors. Because IL-17
production by T cells and other cellular sources is associated
with disease severity, targeting IL-17, which functions upstream
of inflammatory cytokines that result in neutrophil recruitment,
could be desirable, as these play major roles in the development
of ARDS. Additionally, a Th17 dominant immune response
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has been reported to drive more severe viral myocarditis
(226). If azithromycin does blunt IL-17 responses, it could
impact morbidity and mortality related to COVID-19 virally-
induced myocarditis. The studies that characterize the impact
of azithromycin on IL-17-mediated pathology in lymphocyte-
driven airway inflammation in BOS and influenza infection
suggest promise associated with this mechanism (48, 50, 52, 61).
DISCUSSION
Based on the antiviral and immunomodulatory mechanisms
presented, and based on the limited clinical evidence of its impact
on viral clearance, the thorough evaluation of azithromycin as a
possible treatment for patients with COVID-19 is warranted. The
ability of azithromycin to impact the production of inflammatory
mediators through its inhibition of NF-κB and other pro-
inflammatory signaling pathways suggests the potential for
benefit in counteracting the hyperinflammatory state that
manifests through neutrophil influx, lung inflammation,
cytokine storm, and hypercoagulation. It is likely that these
immunomodulatory effects will be beneficial in patients infected
with COVID-19, but careful evaluation of when to utilize the
drug based upon current viral burden and immune status
is critical. This approach has also been proposed in a recent
communication published in The Lancet in which the authors
recommend that patients with COVID-19 should be screened
for hyperinflammation in order to identify the subgroup that
may benefit from immunomodulatory or immunosuppressive
therapies (190).
In conclusion, the immunomodulatory effects of azithromycin
are complex and multifactorial. Impacting macrophage
polarization, autophagy, and cytokine release will likely be
beneficial in a subgroup of patients, but any treatment that
impacts immune function should be used with caution in
patients with an active infection. Until regulatory aspects
of macrophage function are better defined in the setting of
COVID-19, and until azithromycin and other therapies are
properly evaluated in randomized clinical trials in defined
patient populations, extreme caution should be exercised when
utilizing azithromycin in these patients.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
FUNDING
VV was supported by the National Institute of General Medical
Sciences of the National Institutes of Health (NIH) through
award P20GM130456-01 and the National Heart Lung and Blood
Institute (NHLBI) of the NIH through awards R56HL145051
and R01HL152081. AA-L was supported by the NHLBI of the
NIH through award R01HL138488. JG was supported by the
National Institute of Neurological Disorders and Stroke (NINDS)
of the NIH through award R01NS091582. TK was supported by
the NINDS of the NIH through award F31NS105443. DF was
supported by the National Institute of Allergy and Infectious
Diseases of the NIH through award R01AI095307.
REFERENCES
1. Mosholder AD,Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular
risks with azithromycin and other antibacterial drugs. N Engl J Med. (2013)
368:1665–8. doi: 10.1056/NEJMp1302726
2. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin
in children with cystic fibrosis: a randomised, placebo-controlled crossover
trial. Lancet. (2002) 360:978–84. doi: 10.1016/s0140-6736(02)11081-6
3. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene
DA, et al. Azithromycin in patients with cystic fibrosis chronically infected
with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. (2003)
290:1749–56. doi: 10.1001/jama.290.13.1749
4. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long
term treatment with azithromycin on disease parameters in cystic fibrosis: a
randomised trial. Thorax. (2002) 57:212–6. doi: 10.1136/thorax.57.3.212
5. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term
effects of azithromycin in patients with cystic fibrosis: a double blind, placebo
controlled trial. Thorax. (2006) 61:895–902. doi: 10.1136/thx.2005.057950
6. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-
Trnka J, et al. Effect of azithromycin on pulmonary function in patients
with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized
controlled trial. JAMA. (2010) 303:1707–15. doi: 10.1001/jama.2010.563
7. Cigana C, Assael BM, Melotti P. Azithromycin selectively
reduces tumor necrosis factor alpha levels in cystic fibrosis
airway epithelial cells. Antimicrob Agents Chemother. (2007)
51:975–81. doi: 10.1128/AAC.01142-06
8. Stellari FF, Sala A, Donofrio G, Ruscitti F, Caruso P, Topini TM, et
al. Azithromycin inhibits nuclear factor-kappaB activation during lung
inflammation: an in vivo imaging study. Pharmacol Res Perspect. (2014)
2:e00058. doi: 10.1002/prp2.58
9. Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T,
Munic V, et al. Azithromycin distinctively modulates classical
activation of human monocytes in vitro. Br J Pharmacol. (2012)
165:1348–60. doi: 10.1111/j.1476-5381.2011.01576.x
10. Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects
of azithromycin on zymosan-induced production of proinflammatory
mediators by human corneal epithelial cells. Invest Ophthalmol Vis Sci. (2010)
51:5623–9. doi: 10.1167/iovs.09-4992
11. Kanoh S, Rubin BK. Mechanisms of action and clinical application of
macrolides as immunomodulatory medications. Clin Microbiol Rev. (2010)
23:590–615. doi: 10.1128/CMR.00078-09
12. Haydar D, Cory TJ, Birket SE, Murphy BS, Pennypacker KR, Sinai AP, et al.
Azithromycin polarizes macrophages to an M2 phenotype via inhibition of
the STAT1 and NF-kappaB signaling pathways. J Immunol. (2019) 203:1021–
30. doi: 10.4049/jimmunol.1801228
13. Lendermon EA, Coon TA, Bednash JS, Weathington NM, McDyer
JF, Mallampalli RK. Azithromycin decreases NALP3 mRNA stability in
monocytes to limit inflammasome-dependent inflammation. Respir Res.
(2017) 18:131. doi: 10.1186/s12931-017-0608-8
14. Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P,
Zlabinger GJ. Azithromycin inhibits IL-1 secretion and non-canonical
inflammasome activation. Sci Rep. (2015) 5:12016. doi: 10.1038/srep12016
15. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, et
al. Azithromycin blocks autophagy and may predispose cystic fibrosis
patients to mycobacterial infection. J Clin Invest. (2011) 121:3554–
63. doi: 10.1172/JCI46095
Frontiers in Immunology | www.frontiersin.org 13 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
16. Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, et al. Macrolide
antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic
reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol.
(2013) 42:1541–50. doi: 10.3892/ijo.2013.1870
17. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results
of an open-label non-randomized clinical trial. Int J Antimicrob Agents.
(2020) 56:105949. doi: 10.1016/j.ijantimicag.2020.105949
18. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller
R, et al. Imbalanced host response to SARS-CoV-2 drives development of
COVID-19. Cell. (2020) 181:1036–45.e9. doi: 10.1016/j.cell.2020.04.026
19. Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, et
al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir
Med. (2020) 8:750–2. doi: 10.1016/S2213-2600(20)30222-8
20. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress.
JAMA. (2020) 323:2329–30. doi: 10.1001/jama.2020.6825
21. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et
al. Should we stimulate or suppress immune responses in COVID-
19? Cytokine and anti-cytokine interventions. Autoimmun Rev. (2020)
19:102567. doi: 10.1016/j.autrev.2020.102567
22. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses.Nat Rev
Microbiol. (2019) 17:181–92. doi: 10.1038/s41579-018-0118-9
23. Yang Y, Xiao Z, Ye K, He X, Sun B, Qin Z, et al. SARS-CoV-
2: characteristics and current advances in research. Virol J. (2020)
17:117. doi: 10.1186/s12985-020-01369-z
24. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the
receptor-binding domain (RBD) of 2019 novel coronavirus: implication for
development of RBD protein as a viral attachment inhibitor and vaccine. Cell
Mol Immunol. (2020) 17:613–20. doi: 10.1038/s41423-020-0400-4
25. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in
cardiometabolic disease: recent insights from the laboratory and
clinical trials of DPP4 inhibition. Circ Res. (2015) 116:1491–
504. doi: 10.1161/CIRCRESAHA.116.305665
26. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue
distribution of ACE2 protein, the functional receptor for SARS coronavirus.
A first step in understanding SARS pathogenesis. J Pathol. (2004) 203:631–
7. doi: 10.1002/path.1570
27. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed
states: a clinical-therapeutic staging proposal. J Heart Lung Transplant.
(2020) 39:405–7. doi: 10.1016/j.healun.2020.03.012
28. Cron RQ, Chatham WW. The rheumatologist’s role in COVID-19. J
Rheumatol. (2020) 47:639–42. doi: 10.3899/jrheum.200334
29. Channappanavar R, Perlman S. Pathogenic human coronavirus infections:
causes and consequences of cytokine storm and immunopathology. Semin
Immunopathol. (2017) 39:529–39. doi: 10.1007/s00281-017-0629-x
30. Clay C, Donart N, Fomukong N, Knight JB, Lei W, Price L, et al. Primary
severe acute respiratory syndrome coronavirus infection limits replication
but not lung inflammation upon homologous rechallenge. J Virol. (2012)
86:4234–44. doi: 10.1128/JVI.06791-11
31. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al.
Clinical progression and viral load in a community outbreak of coronavirus-
associated SARS pneumonia: a prospective study. Lancet. (2003) 361:1767–
72. doi: 10.1016/s0140-6736(03)13412-5
32. Wang WK, Chen SY, Liu IJ, Kao CL, Chen HL, Chiang BL, et al. Temporal
relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical
progression in patients with severe acute respiratory syndrome. Clin Infect
Dis. (2004) 39:1071–5. doi: 10.1086/423808
33. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-
19: immunology and treatment options. Clin Immunol. (2020)
215:108448. doi: 10.1016/j.clim.2020.108448
34. Merad M, Martin JC. Pathological inflammation in patients with COVID-
19: a key role for monocytes and macrophages. Nat Rev Immunol. (2020)
20:355–62. doi: 10.1038/s41577-020-0331-4
35. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al.
Clinical and microbiological effect of a combination of hydroxychloroquine
and azithromycin in 80 COVID-19 patients with at least a six-day
follow up: a pilot observational study. Travel Med Infect Dis. (2020)
34:101663. doi: 10.1016/j.tmaid.2020.101663
36. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as
a promising strategy for the treatment of emerging viral diseases. Pharmacol
Res Perspect. (2017) 5:e00293. doi: 10.1002/prp2.293
37. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D,
Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical
benefit with the combination of hydroxychloroquine and azithromycin
in patients with severe COVID-19 infection. Med Mal Infect. (2020)
50:384. doi: 10.1016/j.medmal.2020.03.006
38. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin
JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage
in United States veterans hospitalized with Covid-19. medRxiv.
(2020). doi: 10.1101/2020.04.16.20065920
39. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et
al. Early treatment of COVID-19 patients with hydroxychloroquine and
azithromycin: a retrospective analysis of 1061 cases in Marseille, France.
Travel Med Infect Dis. (2020) 35:101738. doi: 10.1016/j.tmaid.2020.101738
40. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K,
et al. Treatment with hydroxychloroquine, azithromycin, and combination
in patients hospitalized with COVID-19. Int J Infect Dis. (2020) 97:396–
403. doi: 10.1016/j.ijid.2020.06.099
41. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral
responses in bronchial epithelial cells. Eur Respir J. (2010) 36:646–
54. doi: 10.1183/09031936.00095809
42. Schogler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C,
Kieninger E, et al. Novel antiviral properties of azithromycin
in cystic fibrosis airway epithelial cells. Eur Respir J. (2015)
45:428–39. doi: 10.1183/09031936.00102014
43. Menzel M, Akbarshahi H, Bjermer L, Uller L. Azithromycin induces anti-
viral effects in cultured bronchial epithelial cells from COPD patients. Sci
Rep. (2016) 6:28698. doi: 10.1038/srep28698
44. Li C, Zu S, Deng YQ, Li D, Parvatiyar K, Quanquin N, et al. Azithromycin
protects against Zika virus infection by upregulating virus-induced type I and
III interferon responses. Antimicrob Agents Chemother. (2019) 63:e00394–
19. doi: 10.1128/AAC.00394-19
45. Feola DJ, Garvy BA, Cory TJ, Birket SE, Hoy H, Hayes D, et
al., et al. Azithromycin alters macrophage phenotype and pulmonary
compartmentalization during lung infection with pseudomonas. Antimicrob
Agents Chemother. (2010) 54:2437–47. doi: 10.1128/AAC.01424-09
46. Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, Broide
D, et al. An antiinflammatory role for IKKbeta through the inhibition
of “classical” macrophage activation. J Exp Med. (2008) 205:1269–
76. doi: 10.1084/jem.20080124
47. Al-Darraji A, Haydar D, Chelvarajan L, Tripathi H, Levitan B, Gao
E, et al. Azithromycin therapy reduces cardiac inflammation and
mitigates adverse cardiac remodeling after myocardial infarction:
potential therapeutic targets in ischemic heart disease. PLoS ONE. (2018)
13:e0200474. doi: 10.1371/journal.pone.0200474
48. Lee N, Wong CK, Chan MCW, Yeung ESL, Tam WWS, Tsang OTY, et
al. Anti-inflammatory effects of adjunctive macrolide treatment in adults
hospitalized with influenza: a randomized controlled trial. Antiviral Res.
(2017) 144:48–56. doi: 10.1016/j.antiviral.2017.05.008
49. Gensel JC, Kopper TJ, Zhang B, Orr MB, Bailey WM. Predictive screening
of M1 and M2 macrophages reveals the immunomodulatory effectiveness
of post spinal cord injury azithromycin treatment. Sci Rep. (2017)
7:40144. doi: 10.1038/srep40144
50. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE.
Azithromycin reduces airway neutrophilia and interleukin-8 in patients
with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. (2006)
174:566–70. doi: 10.1164/rccm.200601-071OC
51. Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic
Z, et al. Azithromycin modulates neutrophil function and
circulating inflammatory mediators in healthy human subjects. Eur
J Pharmacol. (2002) 450:277–89. doi: 10.1016/s0014-2999(02)02
042-3
52. Vos R, Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Neyrinck
A, et al. Azithromycin and the treatment of lymphocytic airway
inflammation after lung transplantation. Am J Transplant. (2014) 14:2736–
48. doi: 10.1111/ajt.12942
Frontiers in Immunology | www.frontiersin.org 14 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
53. Vanaudenaerde BM, Wuyts WA, Geudens N, Dupont LJ, Schoofs K, Smeets
S, et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release
from human airway smooth muscle cells. Am J Transplant. (2007) 7:76–
82. doi: 10.1111/j.1600-6143.2006.01586.x
54. Cheung PS, Si EC, Hosseini K. Anti-inflammatory activity of azithromycin
as measured by its NF-kappaB, inhibitory activity. Ocul Immunol Inflamm.
(2010) 18:32–7. doi: 10.3109/09273940903359725
55. Matsumura Y, Mitani A, Suga T, Kamiya Y, Kikuchi T, Tanaka
S, et al. Azithromycin may inhibit interleukin-8 through
suppression of Rac1 and a nuclear factor-kappa B pathway in
KB cells stimulated with lipopolysaccharide. J Periodontol. (2011)
82:1623–31. doi: 10.1902/jop.2011.100721
56. Iwamoto S, Kumamoto T, Azuma E, Hirayama M, Ito M, Amano K, et
al. The effect of azithromycin on the maturation and function of murine
bone marrow-derived dendritic cells. Clin Exp Immunol. (2011) 166:385–
92. doi: 10.1111/j.1365-2249.2011.04480.x
57. Murphy BS, Sundareshan V, Cory TJ, Hayes D Jr, Anstead MI, et al.
Azithromycin altersmacrophage phenotype. J Antimicrob Chemother. (2008)
61:554–60. doi: 10.1093/jac/dkn007
58. Page C, Goicochea L, Matthews K, Zhang Y, Klover P, Holtzman MJ, et
al. Induction of alternatively activated macrophages enhances pathogenesis
during severe acute respiratory syndrome coronavirus infection. J Virol.
(2012) 86:13334–49. doi: 10.1128/JVI.01689-12
59. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V,
et al. Effect of azithromycin on systemic markers of inflammation in patients
with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest. (2012)
142:1259–66. doi: 10.1378/chest.12-0628
60. Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda
K, et al. Azithromycin blocks neutrophil recruitment in pseudomonas
endobronchial infection. Am J Respir Crit Care Med. (2004) 170:1331–
9. doi: 10.1164/rccm.200402-200OC
61. Krenn K, Gmeiner M, Paulus P, Sela N, Torres L, Zins K,
et al. Effects of azithromycin and tanomastat on experimental
bronchiolitis obliterans. J Thorac Cardiovasc Surg. (2015)
149:1194–202. doi: 10.1016/j.jtcvs.2014.11.088
62. Bystrzycka W, Manda-Handzlik A, Sieczkowska S, Moskalik A,
Demkow U, Ciepiela O. Azithromycin and chloramphenicol diminish
neutrophil extracellular traps (NETs) release. Int J Mol Sci. (2017)
18:2666. doi: 10.3390/ijms18122666
63. Bosnar M, Cuzic S, Bosnjak B, Nujic K, Ergovic G, Marjanovic N,
et al. Azithromycin inhibits macrophage interleukin-1beta production
through inhibition of activator protein-1 in lipopolysaccharide-induced
murine pulmonary neutrophilia. Int Immunopharmacol. (2011) 11:424–
34. doi: 10.1016/j.intimp.2010.12.010
64. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation
of NF-kappaB, but not NFAT, through calcineurin-independent
signaling in T cells. Antimicrob Agents Chemother. (1999)
43:2678–84. doi: 10.1128/AAC.43.11.2678
65. Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik JJ, Jutz S, et al.
Azithromycin suppresses CD4(+) T-cell activation by direct modulation of
mTOR activity. Sci Rep. (2014) 4:7438. doi: 10.1038/srep07438
66. Morikawa K, Zhang J, Nonaka M, Morikawa S. Modulatory effect of
macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J
Antimicrob Agents. (2002) 19:53–9. doi: 10.1016/s0924-8579(01)00457-5
67. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac
injury with mortality in hospitalized patients with COVID-19 in Wuhan,
China. JAMA Cardiol. (2020) 5:802–10. doi: 10.1001/jamacardio.2020.
0950
68. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality
due to COVID-19 based on an analysis of data of 150 patients fromWuhan,
China. Intensive Care Med. (2020) 46:846–8. doi: 10.1007/s00134-020-05
991-x
69. Inciardi RM, Lupi L, Zaccone G, Italia L, RaffoM, Tomasoni D, et al. Cardiac
involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA
Cardiol. (2020) 5:819–24. doi: 10.1001/jamacardio.2020.1096
70. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. (2020)
130:2202–5. doi: 10.1172/JCI137647
71. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and
immunological features of severe and moderate coronavirus disease 2019.
J Clin Invest. (2020) 130:2620–9. doi: 10.1172/JCI137244
72. Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J.
Accumulation, release and subcellular localization of azithromycin
in phagocytic and non-phagocytic cells in culture. Int J Tissue React.
(1994) 16:211–20.
73. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation
in elderly patient. Acta Biomed. (2006) 77:30–2. Available online at: https://
mattioli1885journals.com/index.php/actabiomedica/article/view/1985
74. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as
a cause of QT-interval prolongation and torsade de pointes in the absence
of other known precipitating factors. J Interv Card Electrophysiol. (2007)
18:243–6. doi: 10.1007/s10840-007-9124-y
75. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation
precipitated by azithromycin. N Z Med J. (2003) 116:U666. Available online
at: http://www.nzma.org.nz/journal/116-1185/666/
76. Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation
associated with azithromycin/amiodarone combination. Pacing Clin
Electrophysiol. (2001) 24:1572–4. doi: 10.1046/j.1460-9592.2001.01572.x
77. Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya
C, et al. The QT interval in patients with COVID-19 treated
with hydroxychloroquine and azithromycin. Nat Med. (2020)
26:808–9. doi: 10.1038/s41591-020-0888-2
78. Pfizer. Zithromax (Azithromycin) [Package Insert]. U.S. Food and Drug
Administration. (2020). Available online at: https://www.accessdata.fda.
gov/spl/data/0d60c32a-e05b-46f0-a7fc-b926cdfe8e2c/0d60c32a-e05b-46f0-
a7fc-b926cdfe8e2c.xml (accessed June 14, 2020).
79. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin
in human serum and tissues. J Antimicrob Chemother. (1990) 25 (Suppl
A):73–82. doi: 10.1093/jac/25.suppl_a.73
80. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo
uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism
of delivery and release at sites of infection. Antimicrob Agents Chemother.
(1989) 33:277–82. doi: 10.1128/aac.33.3.277
81. Giudicessi JR, Ackerman MJ. Azithromycin and risk of
sudden cardiac death: guilty as charged or falsely accused?
Cleve Clin J Med. (2013) 80:539–44. doi: 10.3949/ccjm.80a.1
3077
82. Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-
induced torsade de pointes. Pacing Clin Electrophysiol.
(2007) 30:1579–82. doi: 10.1111/j.1540-8159.2007.00
912.x
83. Li H, Zhou Y, Fan F, Zhang Y, Li X, Yu H, et al. Effect of azithromycin on
patients with diffuse panbronchiolitis: retrospective study of 51 cases. Intern
Med. (2011) 50:1663–9. doi: 10.2169/internalmedicine.50.4727
84. Hui D, Yan F, Chen RH. The effects of azithromycin on patients with diffuse
panbronchiolitis: a retrospective study of 29 cases. J Thorac Dis. (2013)
5:613–7. doi: 10.3978/j.issn.2072-1439.2013.09.01
85. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-
term azithromycin use for treatment of bronchiolitis obliterans syndrome
in lung transplant recipients. J Heart Lung Transplant. (2005) 24:1440–
3. doi: 10.1016/j.healun.2004.08.006
86. Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G, et al.
A randomised controlled trial of azithromycin therapy in bronchiolitis
obliterans syndrome (BOS) post lung transplantation. Thorax. (2015)
70:442–50. doi: 10.1136/thoraxjnl-2014-205998
87. Kingah PL, Muma G, Soubani A. Azithromycin improves lung function
in patients with post-lung transplant bronchiolitis obliterans syndrome: a
meta-analysis. Clin Transplant. (2014) 28:906–10. doi: 10.1111/ctr.12401
88. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., et al.
Azithromycin for prevention of exacerbations of COPD. N Engl J Med.
(2011) 365:689–98. doi: 10.1056/NEJMoa1104623
89. Pomares X, Monton C, Espasa M, Casabon J, Monso E, Gallego M.
Long-term azithromycin therapy in patients with severe COPD and
repeated exacerbations. Int J Chron Obstruct Pulmon Dis. (2011) 6:449–
56. doi: 10.2147/COPD.S23655
Frontiers in Immunology | www.frontiersin.org 15 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
90. Vermeersch K, Gabrovska M, Aumann J, Demedts IK, Corhay JL, Marchand
E, et al. Azithromycin during acute chronic obstructive pulmonary disease
exacerbations requiring hospitalization (BACE). A multicenter, randomized,
double-blind, placebo-controlled trial. Am J Respir Crit Care Med. (2019)
200:857–68. doi: 10.1164/rccm.201901-0094OC
91. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al.
Predictors of chronic obstructive pulmonary disease exacerbation reduction
in response to daily azithromycin therapy. Am J Respir Crit Care Med. (2014)
189:1503–8. doi: 10.1164/rccm.201402-0207OC
92. Hahn DL, Grasmick M, Hetzel S, Yale S, Group AS. Azithromycin for
bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med.
(2012) 25:442–59. doi: 10.3122/jabfm.2012.04.110309
93. Johnston SL, Szigeti M, Cross M, Brightling C, Chaudhuri R,
Harrison T, et al. Azithromycin for acute exacerbations of asthma:
the AZALEA randomized clinical trial. JAMA Intern Med. (2016)
176:1630–7. doi: 10.1001/jamainternmed.2016.5664
94. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James
AL, et al. Effect of azithromycin on asthma exacerbations and quality
of life in adults with persistent uncontrolled asthma (AMAZES): a
randomised, double-blind, placebo-controlled trial. Lancet. (2017) 390:659–
68. doi: 10.1016/S0140-6736(17)31281-3
95. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet
V, et al. Azithromycin for prevention of exacerbations in severe asthma
(AZISAST): a multicentre randomised double-blind placebo-controlled trial.
Thorax. (2013) 68:322–9. doi: 10.1136/thoraxjnl-2012-202698
96. Tian BP, Xuan N, Wang Y, Zhang G, Cui W. The efficacy and safety
of azithromycin in asthma: a systematic review. J Cell Mol Med. (2019)
23:1638–46. doi: 10.1111/jcmm.13919
97. Gentzsch M, Mall MA. Ion channel modulators in cystic fibrosis. Chest.
(2018) 154:383–93. doi: 10.1016/j.chest.2018.04.036
98. Southern KW. Macrolide antibiotics for cystic fibrosis. Paediatr Respir Rev.
(2012) 13:228–9. doi: 10.1016/j.prrv.2012.08.001
99. Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland
M, et al. Pulmonary outcomes associated with long-term azithromycin
therapy in cystic fibrosis. Am J Respir Crit Care Med. (2020) 201:430–
7. doi: 10.1164/rccm.201906-1206OC
100. Iannetta M, Ippolito G, Nicastri E. azithromycin shows anti-zika virus
activity in human glial cells. Antimicrob Agents Chemother. (2017)
61:e01152–17. doi: 10.1128/AAC.01152-17
101. Tyteca D, Van Der Smissen P, Mettlen M, Van Bambeke F, Tulkens PM,
Mingeot-Leclercq MP, et al. Azithromycin, a lysosomotropic antibiotic, has
distinct effects on fluid-phase and receptor-mediated endocytosis, but does
not impair phagocytosis in J774 macrophages. Exp Cell Res. (2002) 281:86–
100. doi: 10.1006/excr.2002.5613
102. Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara
A, et al. Azithromycin, a 15-membered macrolide antibiotic,
inhibits influenza A(H1N1)pdm09 virus infection by interfering
with virus internalization process. J Antibiot (Tokyo). (2019)
72:759–68. doi: 10.1038/s41429-019-0204-x
103. Sandeep S, McGregor K. Energetics based modeling of hydroxychloroquine
and azithromycin binding to the SARS-CoV-2 spike (S)protein - ACE2
complex. ChemRxiv. (2020). doi: 10.26434/chemrxiv.12015792.v2
104. Flight WG, Bright-Thomas RJ, Tilston P, Mutton KJ, Guiver M, Morris J, et
al. Incidence and clinical impact of respiratory viruses in adults with cystic
fibrosis. Thorax. (2014) 69:247–53. doi: 10.1136/thoraxjnl-2013-204000
105. Jafarinejad H, Moghoofei M, Mostafaei S, Salimian J, Azimzadeh
Jamalkandi S, Ahmadi A. Worldwide prevalence of viral infection in
AECOPD patients: a meta-analysis. Microb Pathog. (2017) 113:190–
6. doi: 10.1016/j.micpath.2017.10.021
106. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement
of survival in patients with diffuse panbronchiolitis treated with low-
dose erythromycin. Am J Respir Crit Care Med. (1998) 157:1829–
32. doi: 10.1164/ajrccm.157.6.9710075
107. Oda H, Kadota J, Kohno S, Hara K. Erythromycin
inhibits neutrophil chemotaxis in bronchoalveoli of diffuse
panbronchiolitis. Chest. (1994) 106:1116–23. doi: 10.1378/chest.106.4.
1116
108. Banjanac M, Munic Kos V, Nujic K, Vrancic M, Belamaric D,
Crnkovic S, et al. Anti-inflammatory mechanism of action of
azithromycin in LPS-stimulated J774A.1 cells. Pharmacol Res. (2012)
66:357–62. doi: 10.1016/j.phrs.2012.06.011
109. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, et
al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1
activation in human bronchial epithelial cells. BiochemBiophys Res Commun.
(2000) 267:124–8. doi: 10.1006/bbrc.1999.1917
110. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi
H, et al. Clarithromycin suppresses lipopolysaccharide-induced
interleukin-8 production by human monocytes through AP-1 and
NF-kappa B transcription factors. J Antimicrob Chemother. (2002)
49:745–55. doi: 10.1093/jac/dkf008
111. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory
effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem
Biophys Res Commun. (2006) 350:977–82. doi: 10.1016/j.bbrc.2006.09.132
112. Aghai ZH, Kode A, Saslow JG, Nakhla T, Farhath S, Stahl GE, et al.
Azithromycin suppresses activation of nuclear factor-kappa B and synthesis
of pro-inflammatory cytokines in tracheal aspirate cells from premature
infants. Pediatr Res. (2007) 62:483–8. doi: 10.1203/PDR.0b013e318142582d
113. Letsiou E, Kitsiouli E, Nakos G, Lekka ME. Mild stretch activates
cPLA2 in alveolar type II epithelial cells independently through the
MEK/ERK and PI3K pathways. Biochim Biophys Acta. (2011) 1811:370–
6. doi: 10.1016/j.bbalip.2010.12.007
114. Niknami M, Patel M, Witting PK, Dong Q. Molecules in focus:
cytosolic phospholipase A2-alpha. Int J Biochem Cell Biol. (2009) 41:994–
7. doi: 10.1016/j.biocel.2008.07.017
115. Munic V, Banjanac M, Kostrun S, Nujic K, Bosnar M, Marjanovic N, et al.
Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively
correlates with cellular accumulation and phospholipidosis. Pharmacol Res.
(2011) 64:298–307. doi: 10.1016/j.phrs.2011.03.011
116. Karin M. The regulation of AP-1 activity by mitogen-activated protein
kinases. J Biol Chem. (1995) 270:16483–6. doi: 10.1074/jbc.270.28.16483
117. Shirakawa F, Saito K, Bonagura CA, Galson DL, Fenton MJ, Webb AC, et
al. The human prointerleukin 1 beta gene requires DNA sequences both
proximal and distal to the transcription start site for tissue-specific induction.
Mol Cell Biol. (1993) 13:1332–44. doi: 10.1128/mcb.13.3.1332
118. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a
caspase-1-activation platform that regulates immune responses and disease
pathogenesis. Nat Immunol. (2009) 10:241–7. doi: 10.1038/ni.1703
119. Locati M, Mantovani A, Sica A. Macrophage activation and polarization as
an adaptive component of innate immunity. Adv Immunol. (2013) 120:163–
84. doi: 10.1016/B978-0-12-417028-5.00006-5
120. Wang N, Liang H, Zen K. Molecular mechanisms that influence
the macrophage m1-m2 polarization balance. Front Immunol. (2014)
5:614. doi: 10.3389/fimmu.2014.00614
121. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2
macrophages and the Th1/Th2 paradigm. J Immunol. (2000) 164:6166–
73. doi: 10.4049/jimmunol.164.12.6166
122. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage
subsets. Nat Rev Immunol. (2011) 11:723–37. doi: 10.1038/nri3073
123. Nahrendorf M, Swirski FK. Abandoning M1/M2 for a network
model of macrophage function. Circ Res. (2016) 119:414–
7. doi: 10.1161/CIRCRESAHA.116.309194
124. van Heeckeren AM, Schluchter MD. Murine models of chronic
Pseudomonas aeruginosa lung infection. Lab Anim. (2002)
36:291–312. doi: 10.1258/002367702320162405
125. Al-Darraji A, Donahue RR, Tripathi H, Peng H, Levitan BM, Chelvarajan L,
et al. Liposomal delivery of azithromycin enhances its immunotherapeutic
efficacy and reduces toxicity in myocardial infarction. Sci Rep. (2020)
10:16596. doi: 10.1038/s41598-020-73593-0
126. Zhang B, BaileyWM, Kopper TJ, OrrMB, Feola DJ, Gensel JC. Azithromycin
drives alternative macrophage activation and improves recovery and tissue
sparing in contusion spinal cord injury. J Neuroinflammation. (2015)
12:218. doi: 10.1186/s12974-015-0440-3
127. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T,
Figueiredo JL, et al. The healing myocardium sequentially mobilizes two
Frontiers in Immunology | www.frontiersin.org 16 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
monocyte subsets with divergent and complementary functions. J Exp Med.
(2007) 204:3037–47. doi: 10.1084/jem.20070885
128. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al.
Myocardial infarction accelerates atherosclerosis. Nature. (2012) 487:325–
9. doi: 10.1038/nature11260
129. Panizzi P, Swirski FK, Figueiredo JL, Waterman P, Sosnovik
DE, Aikawa E, et al. Impaired infarct healing in atherosclerotic
mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol. (2010)
55:1629–38. doi: 10.1016/j.jacc.2009.08.089
130. Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune
mechanisms in cardiac injury and repair. Nat Rev Immunol. (2015) 15:117–
29. doi: 10.1038/nri3800
131. Kopper TJ, McFarlane KE, BaileyWM, OrrMB, Zhang B, Gensel JC. Delayed
azithromycin treatment improves recovery after mouse spinal cord injury.
Front Cell Neurosci. (2019) 13:490. doi: 10.3389/fncel.2019.00490
132. Amantea D, Certo M, Petrelli F, Tassorelli C, Micieli G, Corasaniti MT, et
al. Azithromycin protects mice against ischemic stroke injury by promoting
macrophage transition towards M2 phenotype. Exp Neurol. (2016) 275 Pt
1:116–25. doi: 10.1016/j.expneurol.2015.10.012
133. Varano GP, Parisi V, Adornetto A, Cavaliere F, Amantea D, Nucci C, et al.
Post-ischemic treatment with azithromycin protects ganglion cells against
retinal ischemia/reperfusion injury in the rat.Mol Vis. (2017) 23:911–21.
134. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, et al.
Azithromycin improves macrophage phagocytic function and expression of
mannose receptor in chronic obstructive pulmonary disease.Am J Respir Crit
Care Med. (2008) 178:139–48. doi: 10.1164/rccm.200711-1666OC
135. Wang J, Xie L, Wang S, Lin J, Liang J, Xu J. Azithromycin promotes
alternatively activated macrophage phenotype in systematic lupus
erythematosus via PI3K/Akt signaling pathway. Cell Death Dis. (2018)
9:1080. doi: 10.1038/s41419-018-1097-5
136. Nichols DP, Chmiel JF. Inflammation and its genesis in cystic fibrosis. Pediatr
Pulmonol. (2015) 50 Suppl 40:S39–56. doi: 10.1002/ppul.23242
137. Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, et al. Innate
immunity in cystic fibrosis lung disease. J Cyst Fibros. (2012) 11:363–
82. doi: 10.1016/j.jcf.2012.07.003
138. Gao H, Ying S, Dai Y. Pathological roles of neutrophil-mediated
inflammation in asthma and its potential for therapy as a target. J Immunol
Res. (2017) 2017:3743048. doi: 10.1155/2017/3743048
139. Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive
pulmonary disease. Am J Respir Cell Mol Biol. (2013) 48:531–
9. doi: 10.1165/rcmb.2012-0492TR
140. Potey PM, Rossi AG, Lucas CD, Dorward DA. Neutrophils in the
initiation and resolution of acute pulmonary inflammation: understanding
biological function and therapeutic potential. J Pathol. (2019) 247:672–
85. doi: 10.1002/path.5221
141. Wilms EB, Touw DJ, Heijerman HG. Pharmacokinetics of azithromycin in
plasma, blood, polymorphonuclear neutrophils and sputum during long-
term therapy in patients with cystic fibrosis. Ther Drug Monit. (2006)
28:219–25. doi: 10.1097/01.ftd.0000195617.69721.a5
142. Zhang H, Qiu SL, Tang QY, Zhou X, Zhang JQ, He ZY, et al.
Erythromycin suppresses neutrophil extracellular traps in smoking-
related chronic pulmonary inflammation. Cell Death Dis. (2019)
10:678. doi: 10.1038/s41419-019-1909-2
143. Wales D, Woodhead M. The anti-inflammatory effects of macrolides.
Thorax. (1999) 54 (Suppl. 2):S58–62. doi: 10.1136/thx.54.2008.s58
144. McCain RW, Holden EP, Blackwell TR, Christman JW. Leukotriene
B4 stimulates human polymorphonuclear leukocytes to synthesize and
release interleukin-8 in vitro. Am J Respir Cell Mol Biol. (1994) 10:651–
7. doi: 10.1165/ajrcmb.10.6.8003341
145. Hodge S, Hodge G, Holmes M, Jersmann H, Reynolds PN. Increased CD8
T-cell granzyme B in COPD is suppressed by treatment with low-dose
azithromycin. Respirology. (2015) 20:95–100. doi: 10.1111/resp.12415
146. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya
D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of
clarithromycin in patients with cystic fibrosis lung disease. Mediators
Inflamm. (2004) 13:111–7. doi: 10.1080/09629350410001688495
147. Williams AC, Galley HF, Watt AM, Webster NR. Differential effects of three
antibiotics on T helper cell cytokine expression. J Antimicrob Chemother.
(2005) 56:502–6. doi: 10.1093/jac/dki251
148. Lin SJ, Yan DC, Lee WI, Kuo ML, Hsiao HS, Lee PY. Effect of
azithromycin on natural killer cell function. Int Immunopharmacol. (2012)
13:8–14. doi: 10.1016/j.intimp.2012.02.013
149. Verleden SE, Vos R, Vandermeulen E, Ruttens D, Vaneylen A, Dupont
LJ, et al. Involvement of interleukin-17 during lymphocytic bronchiolitis
in lung transplant patients. J Heart Lung Transplant. (2013) 32:447–
53. doi: 10.1016/j.healun.2012.12.016
150. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, Meyts I, Bullens DM,
Reynders V, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans
syndrome after lung transplantation. Am J Transplant. (2008) 8:1911–
20. doi: 10.1111/j.1600-6143.2008.02321.x
151. Eiwegger T, Gruber S, Geiger C, Mayer E, Dehlink E, Bannert C,
et al. Impact of systemic immuno-suppression after solid organ
transplantation on allergen-specific responses. Allergy. (2011)
66:271–8. doi: 10.1111/j.1398-9995.2010.02475.x
152. Luu NV, Yang J, Qu XJ, Guo M, Wang X, Xian QY, et al. Azithromycin
inhibits neutrophil accumulation in airways by affecting interleukin-17
downstream signals. Chin Med J (Engl). (2012) 125:491–5.
153. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal
regulation of the nitric oxide synthase/arginase balance in mouse bone
marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol.
(1995) 25:1101–4. doi: 10.1002/eji.1830250436
154. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability
regulates T-lymphocyte cell-cycle progression. Blood. (2007)
109:1568–73. doi: 10.1182/blood-2006-06-031856
155. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM,
et al. Suppression of T-cell functions by human granulocyte arginase. Blood.
(2006) 108:1627–34. doi: 10.1182/blood-2006-11-010389
156. Fletcher M, Ramirez ME, Sierra RA, Raber P, Thevenot P, Al-Khami
AA, et al. l-Arginine depletion blunts antitumor T-cell responses by
inducing myeloid-derived suppressor cells. Cancer Res. (2015) 75:275–
83. doi: 10.1158/0008-5472.CAN-14-1491
157. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG,
et al. L-arginine consumption by macrophages modulates the expression
of CD3 zeta chain in T lymphocytes. J Immunol. (2003) 171:1232–
9. doi: 10.4049/jimmunol.171.3.1232
158. Munder M. Arginase: an emerging key player in the
mammalian immune system. Br J Pharmacol. (2009) 158:638–
51. doi: 10.1111/j.1476-5381.2009.00291.x
159. Burrack KS, Morrison TE. The role of myeloid cell activation and arginine
metabolism in the pathogenesis of virus-induced diseases. Front Immunol.
(2014) 5:428. doi: 10.3389/fimmu.2014.00428
160. Yin Z, Pascual C, Klionsky DJ. Autophagy: machinery and regulation.Microb
Cell. (2016) 3:588–96. doi: 10.15698/mic2016.12.546
161. Cadwell K. Crosstalk between autophagy and inflammatory signalling
pathways: balancing defence and homeostasis. Nat Rev Immunol. (2016)
16:661–75. doi: 10.1038/nri.2016.100
162. Esposito S, Tosco A, Villella VR, Raia V, Kroemer G, Maiuri L. Manipulating
proteostasis to repair the F508del-CFTR defect in cystic fibrosis. Mol Cell
Pediatr. (2016) 3:13. doi: 10.1186/s40348-016-0040-z
163. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C,
et al. Defective CFTR induces aggresome formation and lung inflammation
in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol.
(2010) 12:863–75. doi: 10.1038/ncb2090
164. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M, et al.
Targeting autophagy as a novel strategy for facilitating the therapeutic action
of potentiators on DeltaF508 cystic fibrosis transmembrane conductance
regulator. Autophagy. (2012) 8:1657–72. doi: 10.4161/auto.21483
165. De Stefano D, Villella VR, Esposito S, Tosco A, Sepe A, De
Gregorio F, et al. Restoration of CFTR function in patients
with cystic fibrosis carrying the F508del-CFTR mutation.
Autophagy. (2014) 10:2053–74. doi: 10.4161/15548627.2014.97
3737
Frontiers in Immunology | www.frontiersin.org 17 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
166. Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I,
Ferrari E, et al. A novel treatment of cystic fibrosis acting on-
target: cysteamine plus epigallocatechin gallate for the autophagy-
dependent rescue of class II-mutated CFTR. Cell Death Differ. (2016)
23:1380–93. doi: 10.1038/cdd.2016.22
167. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and
immunity. Nat Rev Immunol. (2013) 13:722–37. doi: 10.1038/nri3532
168. Netea-Maier RT, Plantinga TS, van de Veerdonk FL, Smit JW, Netea MG.
Modulation of inflammation by autophagy: consequences for human disease.
Autophagy. (2016) 12:245–60. doi: 10.1080/15548627.2015.1071759
169. Frieman M, Ratia K, Johnston RE, Mesecar AD, Baric RS. Severe
acute respiratory syndrome coronavirus papain-like protease ubiquitin-like
domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB
signaling. J Virol. (2009) 83:6689–705. doi: 10.1128/JVI.02220-08
170. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19
and potential vaccines: Lessons learned from SARS and MERS epidemic.
Asian Pac J Allergy Immunol. (2020) 38:1–9. doi: 10.12932/AP-200220-
0772
171. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS
and MERS: recent insights into emerging coronaviruses. Nat
Rev Microbiol. (2016) 14:523–34. doi: 10.1038/nrmicro.20
16.81
172. Mesev EV, LeDesma RA, Ploss A. Decoding type I and III
interferon signalling during viral infection. Nat Microbiol. (2019)
4:914–24. doi: 10.1038/s41564-019-0421-x
173. Khailany RA, Safdar M, Ozaslan M. Genomic
characterization of a novel SARS-CoV-2. Gene Rep. (2020)
19:100682. doi: 10.1016/j.genrep.2020.100682
174. Qiu M, Shi Y, Guo Z, Chen Z, He R, Chen R, et al. Antibody responses to
individual proteins of SARS coronavirus and their neutralization activities.
Microbes Infect. (2005) 7:882–9. doi: 10.1016/j.micinf.2005.02.006
175. Choe PG, Perera R, Park WB, Song KH, Bang JH, Kim ES, et al. MERS-CoV
antibody responses 1 year after symptom onset, South Korea, 2015. Emerg
Infect Dis. (2017) 23:1079–84. doi: 10.3201/eid2307.170310
176. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to
SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis.
(2020) 71:2027–34. doi: 10.1093/cid/ciaa344
177. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et
al. Temporal profiles of viral load in posterior oropharyngeal saliva
samples and serum antibody responses during infection by SARS-CoV-
2: an observational cohort study. Lancet Infect Dis. (2020) 20:565–
74. doi: 10.1016/S1473-3099(20)30196-1
178. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody
responses to SARS-CoV-2 in patients with COVID-19. Nat Med. (2020)
26:845–8. doi: 10.1038/s41591-020-0897-1
179. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-
converting enzyme 2 is a functional receptor for the SARS coronavirus.
Nature. (2003) 426:450–4. doi: 10.1038/nature02145
180. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing
antibody targets the receptor-binding site of SARS-CoV-2. Nature. (2020)
584:120–4. doi: 10.1038/s41586-020-2381-y
181. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing
antibodies elicited by SARS-CoV-2 infection. Nature. (2020) 584:115–
9. doi: 10.1038/s41586-020-2380-z
182. Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses
with the antiviral interferon response. Adv Virus Res. (2016) 96:219–
43. doi: 10.1016/bs.aivir.2016.08.006
183. Kopecky-Bromberg SA, Martinez-Sobrido L, FriemanM, Baric RA, Palese P.
Severe acute respiratory syndrome coronavirus open reading frame (ORF)
3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J
Virol. (2007) 81:548–57. doi: 10.1128/JVI.01782-06
184. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion
of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. (2020)
17:533–5. doi: 10.1038/s41423-020-0402-2
185. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune
response in patients with coronavirus 2019 COVID-19 in Wuhan, China.
Clin Infect Dis. (2020) 71:762–8. doi: 10.1093/cid/ciaa248
186. Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. 2019-
novel coronavirus (2019-nCoV) infections trigger an exaggerated
cytokine response aggravating lung injury. ChinaXiv. (2020).
doi: 10.12074/202002.00018
187. Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD(2)
expression impair respiratory DC migration, resulting in diminished T cell
responses upon respiratory virus infection in mice. J Clin Invest. (2011)
121:4921–30. doi: 10.1172/JCI59777
188. Andreakos E, Tsiodras S. COVID-19: lambda interferon against
viral load and hyperinflammation. EMBO Mol Med. (2020)
12:e12465. doi: 10.15252/emmm.202012465
189. Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS,
Hartmann R, et al. COVID-19 and emerging viral infections: the case for
interferon lambda. J Exp Med. (2020) 217. doi: 10.1084/jem.20200653
190. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-0
191. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings
of COVID-19 associated with acute respiratory distress syndrome. Lancet
Respir Med. (2020) 8:420–2. doi: 10.1016/S2213-2600(20)30076-X
192. Chen Y, Feng Z, Diao B, Wang R, Wang G, Wang C, et al.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) directly decimates human spleens and lymph nodes. medRxiv.
(2020). doi: 10.1101/2020.03.27.20045427
193. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
(2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
194. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus
associated with human respiratory disease in China.Nature. (2020) 579:265–
9. doi: 10.1038/s41586-020-2008-3
195. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S,
Chiumello D. COVID-19 does not lead to a “Typical” acute
respiratory distress syndrome. Am J Respir Crit Care Med. (2020)
201:1299–300. doi: 10.1164/rccm.202003-0817LE
196. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet.
(2015) 386:995–1007. doi: 10.1016/S0140-6736(15)60454-8
197. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus
infections: implications for SARS. Nat Rev Immunol. (2005)
5:917–27. doi: 10.1038/nri1732
198. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al.
Identification of a novel coronavirus in patients with severe acute respiratory
syndrome. N Engl J Med. (2003) 348:1967–76. doi: 10.1056/NEJMoa030747
199. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, et al. COVID-19
infection induces readily detectable morphological and inflammation-
related phenotypic changes in peripheral blood monocytes, the
severity of which correlate with patient outcome. medRxiv.
(2020). doi: 10.1101/2020.03.24.20042655
200. Leth-Larsen R, Zhong F, Chow VT, Holmskov U, Lu J. The SARS
coronavirus spike glycoprotein is selectively recognized by lung surfactant
protein D and activates macrophages. Immunobiology. (2007) 212:201–
11. doi: 10.1016/j.imbio.2006.12.001
201. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, et al. Chemokine
up-regulation in SARS-coronavirus-infected, monocyte-derived human
dendritic cells. Blood. (2005) 106:2366–74. doi: 10.1182/blood-2004-10-4166
202. Matsuyama R, Nishiura H, Kutsuna S, Hayakawa K, Ohmagari N.
Clinical determinants of the severity of middle east respiratory syndrome
(MERS): a systematic review and meta-analysis. BMC Public Health. (2016)
16:1203. doi: 10.1186/s12889-016-3881-4
203. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of
bronchoalveolar immune cells in patients with COVID-19. Nat Med. (2020)
26:842–4. doi: 10.1038/s41591-020-0901-9
204. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-
spike IgG causes severe acute lung injury by skewing macrophage
responses during acute SARS-CoV infection. JCI Insight. (2019)
4:e123158. doi: 10.1172/jci.insight.123158
205. Frieman MB, Chen J, Morrison TE, Whitmore A, Funkhouser W, Ward JM,
et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I,
Frontiers in Immunology | www.frontiersin.org 18 February 2021 | Volume 12 | Article 574425
Venditto et al. Azithromycin for COVID-19
II and III interferon receptor independent mechanism. PLoS Pathog. (2010)
6:e1000849. doi: 10.1371/journal.ppat.1000849
206. Zhao J, Zhao J, Van Rooijen N, Perlman S. Evasion by stealth:
inefficient immune activation underlies poor T cell response and
severe disease in SARS-CoV-infected mice. PLoS Pathog. (2009)
5:e1000636. doi: 10.1371/journal.ppat.1000636
207. Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, Gassen
A, et al. SKP2 attenuates autophagy through beclin1-ubiquitination and
its inhibition reduces MERS-coronavirus infection. Nat Commun. (2019)
10:5770. doi: 10.1038/s41467-019-13659-4
208. Cong Y, Verlhac P, Reggiori F. The Interaction between nidovirales and
autophagy components. Viruses. (2017) 9:182. doi: 10.3390/v9070182
209. Carmona-Gutierrez D, Bauer MA, Zimmermann A, Kainz K, Hofer SJ,
Kroemer G, et al. Digesting the crisis: autophagy and coronaviruses. Microb
Cell. (2020) 7:119–28. doi: 10.15698/mic2020.05.715
210. Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema
KJ, et al. Chloroquine inhibits autophagic flux by decreasing
autophagosome-lysosome fusion. Autophagy. (2018) 14:1435–
55. doi: 10.1080/15548627.2018.1474314
211. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-
Lartigue J, Crawford JM, et al. Targeting potential drivers of
COVID-19: neutrophil extracellular traps. J Exp Med. (2020)
217:e20200652. doi: 10.1084/jem.20200652
212. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et
al. Neutrophil extracellular traps in COVID-19. JCI Insight. (2020)
5:e138999. doi: 10.1172/jci.insight.138999
213. Lefrancais E, Mallavia B, Zhuo H, Calfee CS, Looney MR. Maladaptive role
of neutrophil extracellular traps in pathogen-induced lung injury. JCI Insight.
(2018) 3:e98178. doi: 10.1172/jci.insight.98178
214. McDonald B, Davis RP, Kim SJ, Tse M, Esmon CT, Kolaczkowska E,
et al. Platelets and neutrophil extracellular traps collaborate to promote
intravascular coagulation during sepsis in mice. Blood. (2017) 129:1357–
67. doi: 10.1182/blood-2016-09-741298
215. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN,
Politou M, et al. Hematological findings and complications of COVID-19.
Am J Hematol. (2020) 95:834–47. doi: 10.1002/ajh.25829
216. Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation
and antithrombotic treatment in coronavirus 2019: a new challenge. Thromb
Haemost. (2020) 120:949–56. doi: 10.1055/s-0040-1710317
217. Haick AK, Rzepka JP, Brandon E, Balemba OB, Miura TA. Neutrophils are
needed for an effective immune response against pulmonary rat coronavirus
infection, but also contribute to pathology. J Gen Virol. (2014) 95:578–
90. doi: 10.1099/vir.0.061986-0
218. Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, Reading PC. The
role of neutrophils during mild and severe influenza virus infections of mice.
PLoS ONE. (2011) 6:e17618. doi: 10.1371/journal.pone.0017618
219. Lim K, Hyun YM, Lambert-Emo K, Capece T, Bae S, Miller R, et al.
Neutrophil trails guide influenza-specific CD8(+) T cells in the airways.
Science. (2015) 349:aaa4352. doi: 10.1126/science.aaa4352
220. Ge C, Monk IR, Monard SC, Bedford JG, Braverman J, Stinear TP, et al.
Neutrophils play an ongoing role in preventing bacterial pneumonia by
blocking the dissemination of Staphylococcus aureus from the upper to
the lower airways. Immunol Cell Biol. (2020) 98:577–94. doi: 10.1111/imcb.
12343
221. Wei H, Xu X, Tian Z, Sun R, Qi Y, Zhao C, et al. Pathogenic T-
cells and inflammatory monocytes incite inflammatory storms in severe
COVID-19 patients. Natl Sci Rev. (2020) 7:998–1002. doi: 10.1093/nsr/nwa
a041
222. Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, et
al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci
Immunol. (2020) 5:eabd6832. doi: 10.1126/sciimmunol.abd6832
223. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith
N, et al. Impaired type I interferon activity and inflammatory
responses in severe COVID-19 patients. Science. (2020) 369:718–
24. doi: 10.1126/science.abc6027
224. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman
BA. MERS-CoV infection in humans is associated with a pro-
inflammatory Th1 and Th17 cytokine profile. Cytokine. (2018)
104:8–13. doi: 10.1016/j.cyto.2018.01.025
225. De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza
L, et al. Marked T cell activation, senescence, exhaustion and skewing
towards TH17 in patients with COVID-19 pneumonia.Nat Commun. (2020)
11:3434. doi: 10.1038/s41467-020-17292-4
226. Myers JM, Cooper LT, Kem DC, Stavrakis S, Kosanke SD, Shevach
EM, et al. Cardiac myosin-Th17 responses promote heart failure in
human myocarditis. JCI Insight. (2016) 1:e85851. doi: 10.1172/jci.insight.
85851
Conflict of Interest: VV, AA-L, JG, and DF have a patent pending for an
azithromycin formulation to modulate immune responses.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Venditto, Haydar, Abdel-Latif, Gensel, Anstead, Pitts, Creameans,
Kopper, Peng and Feola. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 19 February 2021 | Volume 12 | Article 574425
